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Chapter 1.  Introduction 
The Importance of Amorphous Materials 
 Historically, pharmaceutical companies have focused on developing crystalline forms of 
drug molecules and much effort has gone toward discovering and developing the most stable 
crystalline form of a given drug molecule.  Crystalline solids are those that demonstrate regular 
long-range packing order of the molecules, while amorphous solids are disordered at the 
molecular level, with some short-range packing order but lacking the long-range order of a 
crystalline form. (1, 2) Each crystalline form has specific physical properties that may affect 
manufacturing and/or dosing requirements, so it is of great importance to understand and control 
the crystallinity of the drug material during the development process. (3) Developing the most 
stable form will prevent changes in the formulation after manufacture and helps to ensure a 
reliable drug product.    
The most stable crystalline form is the lowest energy state for a solid.  In contrast, the 
amorphous state of a material represents the highest free energy form of that solid system, and 
the amorphous form of a material therefore has the highest crystallization potential. (4) With 
changes in condition, and over time, the amorphous or meta-stable material will always move 
toward the lowest energy state, which is the most stable crystalline form. (3) For this reason, 
understanding the relationship between the crystallization and amorphous states is of great 
interest to pharmaceutical science.   
Amorphous vs. Crystalline Materials 
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Over the past several years there has been increasing interest in the development of 
amorphous materials, particularly on developing low solubility drugs as amorphous materials.  
Along with having higher energy, the amorphous state of a material will have higher solubility 
than its crystalline state. (5) The low solubility of many crystalline drug materials can affect not 
only the bioavailability of the drug, but also presents problems for manufacturing and 
development of the material.  Insoluble drug materials are difficult to work with and the effect in 
vivo may be limited by dissolution as well.  Developing the amorphous form of a drug has the 
potential to offer solubility and bioavailability advantages over the development of a crystalline 
form, provided the stability liability can be overcome. (5, 6)  
 
BCS Classification 
The Biopharmaceutics Classification System is used by the FDA (7, 8) to classify drugs 
into categories according to solubility and permeability, to predict whether bioavailability will be 
a potential issue for drug delivery.  As shown in Figure 1, drug molecules are assigned a box 
based on having high or low solubility and high or low permeability or low metabolism. (7) Low 
solubility drugs with high permeability are often considered to have “solubility-limited” 
bioavailability and formulation strategies are often used to increase the apparent solubility of 
such drugs.  The pie chart in Figure 2 (9) illustrates the relative percentages of different types of 
drugs being developed recently.  The large percentage of Class II drugs with solubility-limited 
bioavailability underscores the importance of developing new manufacturing strategies to 
increase the apparent solubility of potential drug molecules.  Class II drugs, with low solubility 
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but high permeability, are the most likely BCS class of drugs to benefit from solubility 





















Figure 2. The frequency of pharmaceutical drugs found in each class of the different classes of 
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Amorphous Solid Dispersions  
Introduction to Amorphous Solid Dispersions  
One of the techniques being developed for development of drugs in the amorphous state 
is amorphous solid dispersion technology. (11-15) Amorphous Solid Dispersions (ASDs) have 
been shown to help stabilize amorphous materials and enhance dissolution and bioavailability of 
drugs with low solubility.  The first to report enhanced stability using solid dispersions were 
Chiou & Riegelmann. (11, 16) Solid dispersions are used to improve the solubility of the drug, 
increase bioavailability and stabilize the amorphous form of the drug. (17) 
 
Definition of ASDs 
There are several definitions of amorphous solid dispersion found in the literature (15-
18), each describing the solid dispersion in a manner specific to the application being studied.  
Chiou defines ASD as a mixture of amorphous API with an amorphous polymer. (11, 19) For 
this present discussion, a general definition is used:  Amorphous solid dispersion (ASD) is 
defined as a molecular level dispersion of a hydrophobic drug, such as AMG 517, within an 
amorphous matrix material, such as HPMC-AS polymer.   
 
Recent examples and uses of ASDs 
In 1983, Hiroyuki Imaizumi made solid dispersions of indomethacin in PVPP from 
acetone solution and found that indomethacin was stabilized against heat and moisture. (20) In 
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2001, Ping Tong et al. made ASDs of indomethacin and its Na salt by mixing and by co-
precipitation.  They observed phase separation of the physical mixture, but only one Tg for the 
co-precipitated ASD. (21) There was inhibition of crystallization in the dispersion, which they 
believe is due to interaction between the acid and the salt.  A more recent example of a solid 
dispersion is from Jingjun Huang et al. where dispersions of nifedipine in various polymer 
blends were prepared.  They found an increase in Tg from 50°C for amorphous nifedipine to 
115°C for the ASD, as well as enhanced physical stability.  H-bonding was observed between 
nifedipine and polymer, leading to the conclusion that stability is not only due to increased Tg, 
but is also a result of chemical interactions between drug and polymer. (22)  
Other recent literature on the subject includes details on preparation methods for 
amorphous solid dispersions, (23-25) characterization of solid dispersions, (26), (27) using solid 
dispersions to increase dissolution and enhance bioavailability, (15, 17, 28) excipient selection 
for solid dispersions (29, 30), crystallization observations (31-34), understanding how drug-
polymer solubility and miscibility affects stability, (14, 19, 35-37) and prediction of 
crystallization kinetics. (19, 38, 39) The recent explosion of literature dealing with all aspects of 
amorphous solid dispersions shows that this technology has potential for great benefit to the drug 
development process, and that there is still much to be learned about amorphous solid 
dispersions.   
ASD Preparation by Spray Drying  
A primary goal of preparing ASDs is to prepare the drug in such a way that it is 
completely miscible with the polymer. (40, 41) There are several techniques available for ASD 
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preparation, (23, 42) including hot melt extrusion (43-45), melt quenching (46), melt granulation 
(47), solvent evaporation (12) and spray drying (27, 48-52).  Figure 3 illustrates the process of 
spray drying ASDs out of solution.  The “molecularly dispersed solution” contains solvent, 
polymer and drug dissolved together in solution.  The solution is sprayed through a nozzle and 
rapidly dried.  If the drying temperature is below both the crystallization temperature and 
separation temperature, then the solid particles collected are mixed at the molecular level and an 
amorphous solid dispersion results.  If the drying temperature is above the separation 
temperature, then the drug molecules will phase separate and/or crystallize out of the polymer 
carrier.   
 
Figure 3. Spray drying of ASDs (53) 
 
Miscibility & Phase Separation 
Phase separation can happen before or simultaneous with crystallization.  The degree of 













drying (annealing) time.  Figure 4 illustrates the phase separation which can result when an ASD 
















Figure 4. Illustration of ASD phase separation process  
 
The left side of Figure 4 illustrates the situation with drug and polymer dissolved in a 
solvent.  Although it is not the focus of this project, it has also been observed that polymers can 
enhance stability in the solution state. (55) The right side illustrates the composition of the spray 










top to bottom, the circles represent drug molecules in coming together to form larger particles 
which are phase separated from the polymer.  The particles of an ASD may undergo phase 
separation prior to crystallization.  The phase separated particle is more likely to crystallize since 
it has become less kinetically stable.  A drug in a solid dispersion may exist in an amorphous 
state due to the carrier (the polymer) acting to inhibit crystallization. (56)   
In contrast to a physical mixture, the drug and polymer phases in an amorphous solid 
dispersion are indistinguishable.  Individual drug molecules are interspersed between chains of 
polymer, allowing for interaction between drug and polymer.  The latter case, with drug and 
polymer phases indistinguishable, has been demonstrated to provide kinetic stability to a drug-
polymer system.  In this situation, the drug and polymer are distinct phases and there will be 
little, if any, interaction between drug and polymer.  In order to provide the most stability to the 
dispersion, the polymer must mix homogeneously with the drug. (2)  
Miscibility of ASDs is analogous to aqueous solubility.  Aqueous solubility studies 
suggest increased solubility in aqueous systems can be a result of binding interactions between 
the polymer and drug, (55) with drug molecules bound to polymer.  Polymers have been found to 
increase the solubility of aqueous drug solutions due to molecular interactions such as 
electrostatic bonding (ionic and dipole interactions).  Polymer-drug binding affects the 
physicochemical properties of the dispersion and the choice of appropriate polymer used to make 
ASDs can have a significant effect on physical stability.  For some systems, when polymer 
concentration increases, polymer-polymer bonds decrease their ability to form drug complexes.  
Polymer molecules tend to form electrostatic bonds with themselves, limiting their ability to 
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form complexes. (55) Dispersions prepared below the solid solubility limit are more physically 
stable. (54) 
 
Glass Transition & mDSC 
 The glass transition is the primary thermal event associated with amorphous material as it 
undergoes transition from solid to a rubbery liquid phase. The glass transition temperature (Tg) is 
the temperature at which an amorphous “glass” turns into a metastable “supercooled liquid” and 
is commonly measured using modulated DSC technique. (57) Molecular level mixing of ASDs is 
indicated by miscibility, as observed by spectroscopy and a single Tg in DSC. (58) In a phase 
mixed system, dispersed at the molecular level, only one amorphous phase (only one Tg) is 
observed using mDSC.  More than one Tg indicates more than one amorphous phase. (58, 59) A 
polymer blend may be considered miscible when only one Tg is observed. If the components are 
immiscible, a separate Tg is observed for each component. (59) In this way, the presence of a 
single Tg is an indication of miscibility between drug and polymer.   
 The glass transition is a kinetic event influenced by molecular weight (MW), additives 
and thermal history including preparation technique, cooling rate and degree of cure (2, 59) and 
is usually approximately 2/3 to 4/5 of the melting point, Tm (using Kelvin units). (2) If the ASD 
is phase separated, it will show a separate Tg corresponding to each components being mixed.  A 
phase separated system with particle domains < 15-30 nm will also result in a single Tg being 
observed, since the domains are so small as to be virtually indistinguishable from individual 






Figure 5.  Phase diagram  
 
An energy diagram for amorphous and crystalline states is shown in Figure 6 and can be 
used to illustrate glass transition in relation to other thermal parameters. (5) Starting from a point 
on the “glass” (or amorphous) line and increasing temperature, the material increases in Volume/ 
Enthalpy/ Entropy until the Tg is reached.  At the Tg, the slope of the line changes in the super-
cooled liquid zone as the amorphous glass becomes more mobile and reaches the liquid phase as 
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it melts, at Tm.  As energy is decreased at Tm, the stable crystal state is reached.  If the 
amorphous glass material is subjected to annealing conditions, a vertical line can be drawn at the 
annealing temperature indicating the energy change associated with structural relaxation.  As 
temperature is increased, this relaxation energy is recovered when the temperature reaches Tg. 
Understanding the energy diagram is important when considering the storage temperature for 
ASDs.  Moving left along the curve away from the Tg, the material (such as an ASD) becomes 
more stable.   
 
Storage Temperature  
  “The difference between storage temperature and Tg is critical for stability of amorphous 
materials.” (61) High reduced temperature (the difference between Tg and storage temperature) is 
beneficial for stabilizing ASD above 120 ºC. (37) Differences in crystallization rate are not 
explained exclusively by reduced temperature. (62) Glassy solids have molecular mobility up to 
at least 50ºC below Tg.  For this reason, amorphous solid dispersions are recommended to be 
stored below Tg-50ºC. (63) The Tg-50 Rule is dependent on the fragility of the system and 
relaxation behavior. (2) Relaxation of an ASD can also be observed using mDSC, aging, 
annealing or conditions.  Relaxation enthalpy decreases with higher annealing or storage 




Gordon – Taylor Equation 
Several equations have been developed to predict the Tg of solid mixtures, the Gordon-
Taylor equation being the most well known.  The Gordon-Taylor equation is used to predict Tg 
for amorphous mixtures and for miscible blends of drug and polymer.  Water is known to cause a 
decrease in the Tg of amorphous materials.  The Gordon-Taylor equation (1952) can be used to 
predict the Tg of amorphous drug in the presence of water. (65) The Gordon-Taylor equation 
assumes perfect volume additivity with no specific interactions between the components. (66)   
 Gordon-Taylor, 1952   Equation 1 
 
The Gordon-Taylor equation was designed to elucidate the effect of water content on Tg 
and can be extended to tertiary form for ASDs with 3 components and a tertiary form of the G-T 
equation used with a third component such as water or solvent. (32) Combined with the Simha 
Boyer rule, the extended version of the Gordon - Taylor equation for a ternary system with 
solvent or water-containing dispersions is:    
          Equation 2 
 
 
 with K2 = Q1Tg1/Q2Tg2        Equation 3 











where Q is density, where w1 is the lowest Tg material and w3 is the higher Tg material. (23, 61) 
Other Tg models can be compared with the traditional Gordon-Taylor model, such as the 




All of these Tg prediction models assume no interaction between components of the 
mixture (Truong, 31) “For complete miscibility, interactions between the two components are 
necessary.  A miscible system can phase separate and become unstable if specific interactions 
between the components are adversely affected by a 3rd component like water.” (54) Deviation 
from Gordon-Taylor and other Tg prediction models indicates some type of interaction in the 
system.  Studies of drug-excipient interactions in dispersions can be evaluated using 
thermodynamic phase diagrams such as a graph of temperature versus % drug. (69-71) Another 
study has reported mixed phase Tg analysis (23) with TGA being used to determine % water, 
drug content measured by HPLC and the polymer fraction is determined from the difference 
(100-H2O-drug). (23)  
Examples of both positive and negative deviation from Gordon-Taylor ideality have been 
reported.  One list of polymer Tg values (69) shows, among other things, that Tg was depressed 
more with higher % PVP. (62, 72) Depression of the Tg with respect to Gordon-Taylor 
predictions has also been observed for itraconazole-HPMC melt extrusions. (25) Negative 













less than the drug-drug or polymer-polymer interactions. (73) A study with BMS488043 is an 
example of a higher Tg being observed for ASD compared with drug alone and indicates strong 
interactions between drug and polymer. (61)  
The intermolecular interactions and self-associations determine the extent of deviation 
from Gordon-Taylor ideality and it has been suggested that miscibility is mainly the result of the 
balance between adhesion and cohesion forces. (23, 66) Self-association among any of the 
components results in higher free volume than expected from ideal mixing, leading to higher 
molecular mobility, and lower Tg values. On the other hand, interaction between components 
results in lower free volume and higher Tg values. (66, 70)  
Possible explanations for negative Tg deviation are: 1) Undetected phase separation, 
although this is unlikely if a single Tg is observed, 2) ASDs produced using slower cooling rates 
have lower Tg than quickly cooled ASDs, configurational entropy being stored in the glass after 
cooling or 3) if molecular forces between drug and polymer are weaker than self-associating 
interactive drug-drug or polymer-polymer forces. (23) It is well known that Tg is depressed and 
broadened in the presence of moisture, increasing molecular mobility and decreasing the 
activation energy for crystallization. (62) In order for negative deviation, or Tg depression, to 
happen, the free volume in the homogeneous mixture must be larger than for the phase mixed 
material. (25)  
An explanation of broad Tg regions is related to drug-polymer mixing, aided by water 
evaporation.  Water may block drug-polymer H-bonding if it is sorbed onto the polymer. (25) 
Water is a plasticizer for many amorphous materials. (74) Stability against crystallization is 
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consistent with degree of supersaturation and it can be said that increased RH decreases Tg.  
Following adsorption of water, Tg is reduced and systems are described as plasticized.  Increased 
water sorption leads to reduced Tg, relative to dry material. (62) 
In summary, the presence of a single Tg is a commonly used and important, though not 
an infallible, indicator of miscibility, since it provides an indication of phase mixing and 
miscibility, but no information about the thermodynamics of mixing. (75) Deviation from ideal 
G-T behavior can be due to: 1) water competing with drug for interaction with polymer, 2) 
interaction between drug and polymer causing increased free volume of the homogeneous phase, 
or 3) formation of a polymer-rich phase. (25) 
 
Crystallization Kinetics  
Traditional Solid State Stability 
It is necessary to identify stable conditions of a drug in development.  Traditional solid 
state experiments are carried out at accelerated stability conditions using elevated temperatures 
and/or high humidity conditions.  Stability results are typically reported as < or > over a 
specified time during which the sample is held at the specified condition.  The common reporting 
non-specific stability results is due to difficulty in obtaining more specific crystallization rate 
data on solids, and because crystallization rate models are sometimes difficult to fit.  However, 
crystallization rate models do exist, and isothermal microcalorimetry can provide continuous 
crystallization data for accelerated conditions which can be compared with the various models, 
then extrapolated back to determine room temperature stability for the materials.  
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Both thermodynamic and kinetic factors are involved in stabilization of solid dispersions. 
(37) Miscibility between a drug and polymer reduces the chemical potential of the drug, which 
reduces the thermodynamic driving force for crystallization. (62) A completely miscible system 
will produce the most thermodynamically stable situation for an ASD.  The phase separation 
process will usually happen before nucleation and crystal growth occur for an ASD but may also 
occur simultaneously.  The extent of phase mixing and phase separation for an ASD impacts the 
ability of the ASD to stabilize the amorphous drug against crystallization. (60) Understanding the 
crystallization rate of miscible and partially miscible ASDs is critical for the development of 
amorphous drugs as solid dispersions.   
 
Nucleation and Crystal Growth 
Crystallization, the “process by which a super-cooled liquid (glass) undergoes a first 
order phase transition to form the thermodynamically more stable crystallization phase,” 
involves nucleation and growth.  (19) “The nucleation-growth model recognizes two distinct 
steps in crystallization that have different temperature dependence: the lower temperature favors 
nucleation and the higher temperature favors growth.”  Crystallization involves nucleation and 
crystal growth and is governed by the diffusion rate of molecules. (72)  
Nucleation rate is governed by the activation energy, Ea, required to develop stable nuclei 
and molecule diffusion. (76) The nucleation-growth model says that nucleation is preferred by 
low temperature, where growth is preferred by high temperatures and rapid cooling can prevent 
nucleation. (2) Slow cooling allows more time for nucleation to occur, whereas fast cooling can 
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prevent full nucleation, stabilizing the amorphous state of the dispersion.  Excess energy “along 
with surface tension gives the work necessary to form a nucleus of critical size.” (2) From a 
simulation of crystal nucleation in suspensions of colloid spheres with varying PS distribution, it 
was determined that the probability of critical nuclei forming goes through a maximum as super-
saturation increases. (77)   
 
Kinetic Models 
 The rate of crystallization can be determined using equations derived from crystallization 
theory, such as the Johnson-Mehl-Avrami (or JMA) equation.  Kinetic models include those 
developed by Avrami (1939, 1940, 1941), Sheridan/Anwar (1996), Supaphol/Spruiell (2001), 
Wellen/Rabello (2005), Yang (2005), Khawam/Flanagan (2006), Ziaee/Supaphol (2006) and 
Prout/Tompkins (1944). (16) The general kinetic equation for crystallization is  
dα/dt = k(T)f(α)         Equation 6 
where dα/dt is the fraction crystallized, k(T) is a rate constant function and f(α) is the reaction 
model equation. (32) Johnson-Mehl-Avrami (JMA) theory is the most commonly used for the 
determination of crystallization rate constants of amorphous materials, (78) with the following 
equation being used to determine isothermal induction time and rate constants.  
α= 1-exp[-Ktm],         Equation 7 
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where α is the fraction crystallized, K is crystallization rate, t is time of crystallization and m is 
the reaction order which depends on the nucleation mechanism (m=2 for rods, m=3 for plates). 
(78) Differentiation of the above equation gives (79) 
dα/dt= Km(1-α)[-ln(1-α)]1-1/m        Equation 8 
 
For the JMA equation to be valid, the growth rate of the new phase must be 1) controlled 
by temperature, 2) independent of time and 3) have low anisotropy of crystals. (79) The Avrami 
equation is based on a couple assumptions: 1) that the nucleation rate is constant with respect to 
time and 2) that crystallization grows linearly with respect to crystallization time.  These 
assumptions lead to an over-prediction of crystallization rate because the nucleation rate 
decreases when the nucleation sites are used up. (16) However, the JMA equation is valid in 
isothermal conditions for nucleation at randomly dispersed second phase particles, such as would 
be found in a molecularly dispersed ASD.  The growth rate of the new phase should be 
controlled by temperature and independent of time. (79)  
After calculating the rate constant K using the JMA equation for each crystallization 
condition, the Arrhenius equation (below) can be applied to the crystallization data:   
ln k = ln A – Ea/RT         Equation 9  
where k is the crystallization rate, A is a constant, Ea is the activation energy, R is the gas 
constant and T is temperature.  A plot of ln k v 1/T (in Kelvin units) has slope of Ea/R, giving 
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activation energy Ea for the material. (80) The Arrhenius equation can also be extrapolated to 
predict the rate constant at extended temperature. 
The kinetic crystallization equation may not strictly follow Arrhenius behavior because 
activation energies (Ea) of nucleation and growth can have different temperature dependencies.  
Therefore the overall rate won’t usually follow Arrhenius behavior. (32).  The different apparent 
Ea from isothermal and non-isothermal experiments can tell something about the underlying 
mechanisms of crystallization (78) and at least one study has been reported where nucleation and 
crystal growth were studied separately to establish the crystallization mechanism.” (32)  
 
The Role of Water  
Residual water can have an effect on physical and chemical properties of drugs in the 
solid state. (81) There is a competing effect between the polymer increasing hygroscopicity and 
the thermodynamic effect of combining drug with polymer. (62) “Water acts as a plasticizer to 
produce significant increase in molecular mobility” (81) which lowers the Tg and increases the 
crystallization rate.  However, water sorbed to the amorphous glass can also inhibit the 
rearrangement needed for crystallization, inhibiting crystallization. (32) Water sorbed between 
drug and excipient can facilitate interactions to catalyze degradation or stabilize the amorphous 
state. (81-83) Water sorption may also increase defects and disrupt the crystallization process. 
(32)  
The effect of water on solid state properties depends on regions of higher energy, higher 
molecular disorder and higher mobility.  Water brought in by the excipient can also distribute 
27 
 
into the vapor phase.  This becomes important if the excipient water escapes into the headspace. 
Sorbed water between the drug and excipient can facilitate interaction. If the drug molecules 
move into the structure of the plasticized polymer, this could help stabilize the amorphous phase. 
High RH conditions would affect this interaction. (81) Plasticizing effects of residual solvent, 
absorbed water and additives can be significant to the stability of amorphous materials and are 
difficult to quantify or control. (63) High temperature and high RH are expected to accelerate 
any drug-excipient interactions, so it is important to monitor Tg at elevated conditions. (81) 
Overall, we conclude that there may be many different contributing factors for the enhanced 
physical stability provided to amorphous materials by making amorphous solid dispersions.   
 
Overview of Thesis Work 
Kennedy presents a case study of the AMG 517-HPMC-AS amorphous solid dispersion 
system which sets the background for the present work. (84) 
 
AMG 517 
AMG 517 is a BCS Class II drug molecule with low bioavailability with solubility-
limited absorption.  The structure of AMG 517 is shown below. (85) The molecule is no longer 
in development at Amgen, Inc.  The solubility is ~ 0.05 µg/ml and calculated logP = 5.1 for this 
lipophilic molecule.  The freebase has a pKa ~1.8 on the basic nitrogen, and it readily forms salts, 
hydrates, solvates and multiple crystalline forms.  The melting point of the crystalline freebase is 
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229°C, and an amorphous glass transition (Tg) is found around 110°C.  The CF3 group attached 
to the benzyl ring on the end is useful in SS-NMR studies.  The combined properties of AMG 
517 have made it an attractive molecule for investigation of amorphous solid dispersion 
technology.  (84)  
 
Figure 6. Chemical structure of AMG 517. 
ASDs of AMG 517 with HPMC-AS and HPMC were prepared by spray drying and 
physical stability and in vivo exposure were evaluated.  SEM showed solid, collapsed, 
corrugated particles.  Particle size was 29-40µm.  Dissolution was improved for spray dried 
amorphous AMG 517 compared with crystallized AMG 517 and pharmcokinetic studies with the 











Figure 7. Chemical structure of HPMC-AS (Shin-Etsu) 
 
HPMC-AS (Hydroxypropyl methylcellulose acetate succinate) is a water-soluble polymer 
with weight-average MW between 17,000 and 20,000 (86) and Tg approximately 117°C. (87) 
HPMC-AS has been found to be an effective polymer for use with amorphous solid dispersions 
of low solubility drugs in studies with several drugs including griseofulvin, nifedipine and AMG 
517. (84, 88) The effect of PVP v HPMC-AS on kinetics of solid dispersions with felodipine was 
also studied and the physical stability of ASDs was found to be highly dependent on the choice 
of polymer used, and HPMC-AS was specifically found to be better than PVP. (19)  
HPMC-AS absorbs moisture from the atmosphere, the amount absorbed being dependent 
on the initial moisture content, the temperature and humidity, (25) so controlling crystallization 















increased the induction time for solid dispersion with naproxen, (76) so it should be expected 
that higher drug load ASDs will crystallize faster. 
 
Project Overview 
This project focuses on examining the solid state properties of AMG 517, a BCS Class II 
drug, manufactured by spray drying as amorphous solid dispersions with HPMC-AS polymer, 
and stability using isothermal microcalorimetry and solid state NMR.   
Chapter 2 describes several techniques used to evaluate ASDs and what information each 
technique or method provides.  The techniques include X-ray powder diffraction (XRPD), 
HPLC, gas chromatography (GC), thermal gravimetric analysis (TGA), modulated differential 
scanning calorimetry (mDSC), scanning electron microscopy (SEM), particle size distribution 
analysis (PS),  vapor sorption (DVS), isothermal microcalorimetry (TAM), and solid state 
nuclear magnetic resonance spectroscopy (SSNMR).   
Chapter 3 presents the initial ASD characterization data.  Focus is on the importance of 
phase mixing, residual solvent drying and glass transition.   
In Chapter 4, a series of ASDs is crystallized using TAM isothermal microcalorimetry, 
with crystallinity evaluation using 19F SSNMR and rate constant determination using the 
JMA/Avrami model.  Stability predictions are made by applying statistical analysis to the 
crystallization data using JMP design software and compared with traditional solid state stability 
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Many different techniques can be used to understand amorphous solid dispersions.  The 
initial goal of characterization is to confirm the nature of the starting materials which were 
prepared from the spray drying process.  This includes measuring drug load, particle size, surface 
area, residual solvent drying and amorphous content.  Since ASDs are designed to stabilize the 
drug against crystallization, it is important to understand miscibility and phase separation.  The 
miscibility and phase separation of the drug and polymer components of an ASD directly affect 
the propensity for crystallization.  Methods to track changes in crystallinity are critical when 
crystallization is being studied, as well as a way to put it all together and “map the crystallization 
space.”  This chapter will describe the various analytical techniques used to understand the AMG 
517 – HPMC-AS amorphous solid dispersion system.    
 
Techniques to Evaluate Spray Dry Manufacturing  
 
HPLC – confirmation of drug load 
 
High performance liquid chromatography (HPLC) is a commonly used analytical separations 
technique which can be used to quantify the amount of drug in a solution.  A small amount of 
ASD material must be dissolved in a common solvent, in which both drug and polymer 
components of the ASD are soluble.  The ASD solution is pumped through a column of silica 
bonded hydrocarbon chains using a high pressure pump.  The drug and polymer components 
pass through and elute from the column at different rates, allowing for separation of the ASD 
components.  The response of a known standard is compared with the response from the drug 
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passing through the detector, allowing for quantification of the drug in the solution.  The 
presence of impurities and/or degradation products would also be observed in the HPLC 
chromatograms.  This is a common technique in pharmaceutical labs and provides useful 
confirmation of the drug load in various lots of spray dried ASD materials. (1, 2)  
 
Particle Size Distribution – to measure size of ASDs 
 
Particle size distribution and surface area are important indicators of spray drying control.  
A common method of particle size analysis uses laser diffraction. (3) Evaluating the size 
distribution of ASD particles of different lots gives information about the control of the spray 
drying process.  A trend in particle size between lots with varying drug loads may be an 
indication of significant differences due to drug load and different size particles can behave 
differently, in terms of stability.  The effect of particle size on crystallization has previously been 
studied, (4, 5) and it is accepted that particle size has an effect on crystallization rate, so ASDs of 
similar particle size were desired for crystallization studies.     
Techniques to Evaluate Residual Solvent 
 
TGA – to measure residual ethyl acetate solvent 
 
Thermogravimetric analysis (TGA) is commonly used to measure water and solvent loss 
from solid materials.  A sample of ~5mg is placed in a hanging pan which is lowered into a 
temperature controlled furnace.  A heating ramp is applied and the weight of the sample is 
monitored as the temperature is raised, allowing for detection of water and/or solvent loss.   
The percent of residual solvent is calculated by the software, comparing the weight of the 
sample before and after solvent evaporation.  For ASDs of AMG 517 with HPMC-AS, the type 
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of solvent (water, ethyl acetate, etc) and the nature of its bonding to the sample (i.e. residual 
solvent or hydrate) can be inferred from the temperature at which the solvent comes off the 
sample.  However, TGA is a non-specific method and cannot separate the effects of water versus 
solvent at a given temperature.  Therefore, a more specific method such as GC is used to confirm 
the amount of residual solvent (ethyl acetate) in the ASDs.   
 
GC – to quantify residual ethyl acetate solvent 
Gas chromatography (GC) is a gas separations method used to determine the amount of 
residual ethyl acetate solvent in the spray dried ASDs.  All the components of the spray dried 
ASDs are soluble in DMSO, making DMSO a practical solvent for GC analysis.  The boiling 
point of ethyl acetate is relatively low, at 77°C, and the boiling point of DMSO is high, at 189°C 
(6).  The ethyl acetate is separated from the DMSO solvent on the GC column using a 
temperature ramp and flame ionization detector (FID) to detect the different components at 
different temperatures based on boiling point.  The amount of ethyl acetate is determined by 
comparing the peak area response of the sample with peak area response of standard solutions of 
known concentration.  Using known standards of ethyl acetate allows for quantification of the 
ethyl acetate in the ASDs, which can be compared with TGA results.   
 
Techniques to Verify Amorphous Nature of ASDs 
 
SEM – to observe surface of ASD particles 
 
Scanning Electron Microscopy (SEM) is a technique to qualitatively observe the surface of 
particles.  An electron source achieves higher resolution than is possible with light microscopy.  
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The short wavelength of electrons (0.0054 nm) allows for resolution on the order of 1nm or less, 
compared with 0.2 µm for light microscope and 0.1mm for the unaided eye. (7) With spray dried 
ASD particles prepared on a micron (µm) scale, light microscopy is not resolved enough to see 
details about the surface of the particles.  SEM provides a definitive way of observing individual 
crystals growing out of amorphous particles such as the ASDs of AMG 517 in HPMC-AS 
studied here.    
 
XRD – to verify amorphous nature of ASDs 
 
X-ray powder diffraction (XRD) crystallography is a common analytical tool which gives 
information about the crystal structure of a material, based on the diffraction of X-rays off the 
crystal faces. (8, 9) Each crystalline form of a material has a unique pattern of lines or spikes, 
specific to the packing pattern of that polymorphic form.  An amorphous material, including an 
ASD without a regular packing pattern, will show a broad “halo” instead of a pattern of distinct 
peaks.  This is due to the random ordering of molecules in the amorphous material.   
X-ray powder diffraction patterns are used to determine the amorphous or crystalline nature 
of ASD materials and to verify the crystalline form of AMG 517 as it crystallizes out of the 
ASD.  A partially crystalline ASD will show a few distinct peaks overlaid with a broad 
amorphous “halo” pattern.  The lower limit of detection for crystalline material by XRD in an 
amorphous dispersion is about 3%.    Reference standards of crystalline AMG 517 in HPMC-AS 
polymer are prepared at various known mixtures in order to determine the detection limit of the 





Techniques to Evaluate Miscibility and Phase Separation 
Modulated DSC (mDSC) – to measure glass transition 
Differential Scanning Calorimetry (DSC) is a useful technique for understanding the 
thermal properties of a material.  Thermal events such as melting, phase changes and 
recrystallization are routinely detected by DSC measurements.  Modulated DSC (mDSC) is 
especially effective in obtaining glass transition (Tg) values as well as other thermal information 
about amorphous materials.  A sine wave modulation is introduced into the DSC temperature 
program through the software, which allows for de-convolution of overlapping thermal events, 
separating the output into three signals: the total heat flow, the nonreversible (kinetic) heat flow 
and the reversible (heat capacity component) heat flow. (10, 11) It can be used to provide insight 
into polymorphic transformations and to distinguish between multiple Tgs in a sample if the 
difference between Tgs is < 15°C. (11) For ASDs, mDSC is needed to evaluate the Tg of the 
ASDs.  A phase mixed ASD has one Tg, and a phase separated solid dispersion has a separate Tg 
for each component in the system.  The Tg of pure amorphous AMG 517 is ~ 110 °C and the Tg 
of spray dried HPMC-AS polymer is ~125 °C; therefore, the Tg of an ASD of AMG 517 in 
HPMC-AS should be between 110 – 125 °C.   
 Figure 1 shows the traditional DSC heat flow curve for an ASD and the modulated DSC 
(mDSC) curves for the same sample, with thermal events indicated in the different regions of the 
plots.  The normal heat flow plot is shown at the top and the modulated DSC is shown on the 
bottom, with reversible and non-reversible heat flow curves separated out.  In mDSC, the glass 
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transition is seen in the reversing heat flow curve at ~ 104 °C, and the accompanying 
endothermic relaxation of 4.66 J/g is seen in the non-reversing heat flow curve.   
 
 
     
Figure 1.  Traditional DSC v mDSC.  The top plot shows the traditional DSC heat flow curve for 
50% AMG 517 ASD, with thermal events indicated in the different regions of the plot.  The 
modulated DSC is shown below it, with reversible and non-reversible heat flow curves separated 
out.  The glass transition is easily seen in the reversing heat flow curve and the accompanying 
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19F SSNMR – to evaluate relaxation 
Nuclear Magnetic Resonance (NMR) is a spectroscopic technique based on the magnetic 
polarization of the spins in the nucleus of atoms in a molecule and is commonly used for 
compound structure identification based on chemical shifts for liquid samples.  Solid State NMR 
(SSNMR) is emerging as a powerful technique for characterization of solids.  Spectral 
differences between polymorphs reflect the differences in the local environment of the nuclei in 
the sample.  This is useful in detecting differences in crystal packing and even for evaluating 
differences between amorphous forms.   
The classical way to understand NMR is to imagine a vector (a magnetic dipole) precessing 
about a spinning particle in an external magnetic field, as in Figure 2 below.  A nucleus such as 
1H, 13C or 19F with spin I = ½, is chosen for NMR analysis.  In an externally applied magnetic 
field Bo, a spinning nucleus with I = ½ charge creates a magnetic field, with the lower energy     
+ ½ spin oriented in the direction of the magnetic field, Bo, and the higher energy – ½ spin state 
oriented opposite Bo.  When a magnetic pulse is applied to the nucleus, the + ½ spin is excited to 
the higher energy – ½ spin state.  As the precessing excited nucleus returns to the equilibrium 
state, it “relaxes” to give the NMR signal.  The free induction decay (FID) is observed and 
Fourier transformation is used to transform the time domain signal into the frequency domain 










Figure 2.  NMR Theory Diagrams (14) Top left green arrow indicates magnetic moment 
spinning around Bo field.  When a pulse is applied along B1, the magnetic moment is precessing 
around Bo at an angle (top right).  Bottom left shows free induction decay (FID) signal which is 







 SSNMR spectroscopy is versatile technique with high selectivity, the only technique 
which can give information about structure, order and dynamics of solid state materials.  A 
range of nuclei (with I = ½) can be observed, including 1H, 13C, 15N, 31P, 29Si and 19F.  The 
relative sensitivity and natural abundance of these six nuclei are shown in Table 1.  
Table 1. NMR Properties of Common Nuclei (14) 
Nuclei Natural abundance Relative sensitivity 
1H 99.99% 1 
13C 1.13% 0.016 
15N 0.37% 0.001 
19F 100% 0.83 
31P 100% 0.0663 
29Si 4.90% 0.00784 
 
19F is particularly relevant to this discussion since AMG 517 has a CF3 group.  Fluorine, with 
100% natural abundance and high (0.83) relative sensitivity, is a convenient and fast, nucleus to 
measure.  The CF3 group on the molecule is oriented differently between amorphous and 
crystalline forms and gives a strong signal, making it easy to detect differences between the two 






High Speed Spinning and Magic Angle Spinning 
Since SSNMR is dealing with solid samples rather than liquid samples, high speed 
spinning and magic angle spin (MAS) are used to mimic the molecular motion of a liquid sample 
and minimize effect of random orientation of molecules in a solid sample.  Liquid molecules are 
in fast random motion already, giving high resolution of NMR peaks.  In order to get high 
resolution for solids, a spin speed greater than the width of the CSA (chemical shift anisotropy) 
is needed.   
In the SSNMR context, there are several types of interactions going on, indicated by the 
following equation: 
H = Ho + HD + HCS + HQ,       Equation 1 
where Ho is due to the applied magnetic field Bo, HCS is chemical shift interactions that we are 
interested in, HD is a function of 3cos2θ-1 and angular momentum operators and HQ only applies 
for I > ½.  Magic angle spinning (MAS) was introduced to deal with the HD interactions.  To 
eliminate the effect of molecular orientation in the magnetic field, set 3cos2θ-1=0 and solve for θ 
… θ = 54.4°, the “magic angle”.  If the sample is set to spin at a physical orientation of 54.4°, the 
orientation dependence goes to zero.  MAS is standard and SSNMR probes are commonly 
manufactured to run with samples spinning at the magic angle. (14) 
 
Techniques to Evaluate Crystallinity of Stressed ASDs 




SSNMR can be used to measure and quantify the percent crystallinity in ASDs.  The 
amorphous and crystalline forms will give different SSNMR spectra.  Comparing the integrated 
areas of crystalline and amorphous signals in a SSNMR spectrum of an ASD, the amount of 
crystallization for the sample can be determined.  In a partially crystallized ASD sample, there 
will be signal from both amorphous and crystalline material in the sample.  Integrating distinct 
peaks is a straight-forward way to quantify differences in form.  However, when comparing an 
amorphous form with a crystal form of the same molecule, the amorphous signal will be broad, 
since it is an average of all the possible orientations of the molecule, including the orientation of 
the crystal form.   
When the peaks are partially overlapping and quantitation is desired, de-convolution is 
needed to separate the signals from each form of the material.  The percent crystalline can be 
simply calculated as Area Crystalline / Total Area * 100%.  For molecules such as AMG 517 
where the crystal form being studied has two molecules per unit cell, the SSNMR signal shows 
two distinct peaks for the crystal form.  In this case the percent crystallinity is calculated by 
combining the areas of the two crystalline peaks and dividing by the total area of all three peaks.    
 
Crystallization of ASDs 
Traditional Solid State Stability 
Traditionally, solid state stability studies on pharmaceutical formulations in development are 
performed by placing an aliquot of the formulation at elevated temp and/or RH conditions for 
accelerated stability studies.  Typical conditions include 25 °C, 60%RH for controlled room 
temperature, 40°C, 75%RH for accelerated conditions.  (15) Additional accelerated conditions 
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include 60 °C temperature at 30%RH and 75%RH.  Using stability results from three or more 
temperatures, one can extrapolate to lower temperatures to predict the stability of the formulation 
in development.   
A significant drawback to the traditional solid state stability method is the difficulty in 
predicting the endpoint for crystallization and the stability event can easily be missed.  
Traditional stability studies also tend to require gram-scale quantities of material to perform the 
experiment each condition, due to the need for having multiple time points.  Typically the only 
information obtained from these studies is a general timeframe such as “> 6 months stability” at 
a given condition.  
 
 
Isothermal Microcalorimetry to Evaluate Crystallization 
The crystallization of amorphous ASDs of AMG 517 in HPMC-AS can be monitored by 
isothermal microcalorimetry.  Isothermal microcalorimetry has proven to be a sensitive tool to 
monitor slow, low energy thermal events, such as chemical degradation and physical form 
change.  Microcalorimetry is a complementary technique to DSC using a larger sample size and 
higher sensitivity to observe lower energy changes which are undetectable by DSC. (16) 
Isothermal microcalorimetry can be used to monitor crystallization reactions under controlled 
environmental conditions, allowing for control of the crystallization event.  (17)   
Temperature and relative humidity (%RH) are controlled using TAM isothermal 
microcalorimeter instrument.  Miniature humidity chambers are created using hygrostats 
prepared in a small vials and placed inside the sample cup, to control the humidity of the sample.  
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Saturated aqueous salt solutions are available for temperatures from 0-100 °C with 5 - 98% 
humidity range.  Temperature is accurately controlled and isothermal stability is provided by a 
25L water bath (Figure 4) which controls temperature +/-0.0001 °C.  An external water bath 
provides constant force against which the calorimeter heater must work.  This gives the TAM 
extreme sensitivity to 0.1μW and it can detect 10-4 °C temperature difference.  (18) 
Isothermal heat conduction microcalorimetry measures heat flow dQ/dt, in µW units, from 
ongoing processes.  The heat flow curve is integrated over a specific time interval to obtain heat 
Q, in Joules. (19) The peak area of the exotherm is proportional to the crystalline content since 
this relates directly to the heat of the crystallization event. The integrated heat flow of the 
crystallization event is detected by a heat conduction calorimeter.  Heat is channeled from the 
sample cup through thermopiles, utilizing the Seebeck effect – with voltage generated due to 
temperature differences between metal junctions.  The Twin Measuring Principle is used:  The 
sum of the voltages from each pair of detectors (“Peltier Elements”) is connected in series but in 
opposition, so that the resulting signal represents the difference in heat flow between the two 







     
 
Figure 4. Left: The TAM consists of four microcalorimetry channels (orange caps shown) 
immersed in a 25L water bath.  Right: A diagram of the inside of a typical microcalorimeter.  
The sample is placed into a sealed ampoule and lowered into the microcalorimeter using the 
ampoule lifter.  During the experiment, any heat from the reaction is transferred from the 






     
Figure 5. Top: Diagram of sample vessel where measuring cup is placed, surrounded by 
thermopiles which direct heat flow from the sample into the heat sink.  Heat is channeled 
from the sample cup through thermopiles, utilizing the Seebeck effect – with voltage 
generated due to temperature differences between metal junctions.  Bottom: Diagram of 
Peltier elements.  The sum of the voltages from each pair of detectors (“Peltier Elements”) is 
connected in series but in opposition, so that the resulting signal represents the difference in 





The measured heat of a sample varies at higher temperatures due to changing humidity, 
so saturated salt solutions are used to control the humidity in the measuring cup during the 
experiment.  Salt solutions for making hygrostats for this purpose can be referenced in CRC 
Handbook and others. (21, 22) The National Bureau of Standards (23) also has a great reference 
with tables of salt solutions at various temperature and humidity conditions.  A table of relevant 
salt solutions is shown below. 
Table 2. Salt Solutions  
 
Challenges in using isothermal calorimetry for crystallization of ASDs include 1) the 
possible overlap of crystallization and relaxation events (since isothermal microcalorimetry is 
not a specific technique and will detect all heat events associated with a process),  2) possible 
lack of induction period (nuclei formation not detected, if the crystallization conditions chosen 
for the crystallization experiment are too fast), 3) lower drug load samples being extremely 
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stable (such that crystallization is not observed in a relevant period of time) and 4) the potential 
degradation of excipients under high stress conditions, and the potential impact of residual 
solvent for incompletely dried samples.  Previous studies have also discussed the effect of 
sample size (24) and plasticization when Tg drops below the measuring temp (25).   
Sample amount used for the experiment can also have an effect, as increasing the amount 
of sample loaded into the sample cup was found to be a factor in retarding crystallization for (17) 
study.  Another study with lactose also showed that recrystallization happens when the Tg drops 
below the measured temperature (plasticization) (26) so it is important to be aware of how the Tg 
changes with temperature and humidity.   
For this project, isothermal microcalorimetry is used to study and predict the crystallization 
behavior of AMG 517 – HPMC-AS spray dried dispersions by establishing the relative stability 
of various systems under controlled conditions of temperature and %RH.  The intention is to map 
the crystallization behavior as a function of polymer ratio, temperature and RH, and potentially 




 Several techniques for understanding ASDs have been discussed, each technique giving 
slightly different information about the sample.  HPLC, particle sizing and surface area are used 
to confirm the effectiveness of spray drying.   The residual solvent drying process is measured 
using GC and TGA to determine the residual solvent content.  The amorphous nature of the ASD 
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materials is verified with SEM and XRD.  Miscibility and phase separation are evaluated with 
mDSC and SSNMR for glass transition and relaxation measurements, respectively.  Isothermal 
microcalorimetry is used as an alternative to traditional accelerated stability conditions for 
monitoring the crystallization event in solid state stability studies.  Finally, the % crystallinity is 
measured using 19F SSNMR.  Using many different techniques to evaluate a system allows the 
scientist to obtain a thorough understanding of the materials being studied.  Combining all of the 
methods discussed in this chapter should provide a detailed picture of the expected behavior of 
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Chapter 3.  Characterization and Effect of Residual Solvent and Drug Concentration on 
Glass Transition Values of ASDs of AMG 517 and HPMC-AS 
 
Introduction 
Adding a polymer to drug to make amorphous solid dispersions (ASDs) can inhibit 
crystallization in both the solid and solution state for some drug-polymer systems.  AMG 517 
dispersed in HPMC-AS is investigated as a molecular dispersion of drug within a matrix 
material.  The goal of making ASDs is for the drug to be completely miscible in the polymer, as 
this will produce the most stable situation for the amorphous drug.  Drug and polymer phases are 
indistinguishable for an ASD, as the drug and polymer are miscible with each other in one phase.     
The degree of phase separation varies based on preparation technique and drug load.  Spray 
drying is a common manufacturing method for ASDs.  A well controlled spray dry 
manufacturing process produces different lots of ASD material with similar particle size and 
other physical properties.  ASDs for this study are manufactured using HPMC-AS polymer and 
ethyl acetate as solvent.   
Residual solvent is known to have an effect on the glass transition temperature of the 
mixture.  If the ASD is not sufficiently dried of residual solvent, the Tg of the mixture will appear 
lower than the true Tg.  It is therefore important to dry the materials sufficiently prior to 
characterization and use.  Using the Gordon-Taylor model to evaluate the ASD system over a 
range of drug loads can provide insight into the significance of interaction between the 
components of the ASD.   
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X-ray powder diffraction (XRPD) can be used to confirm amorphous nature of ASDs, but 
has a detection limit ~5-10%.  Modulated differential scanning calorimetry (mDSC) is also able 
to provide information about the nature of the manufactured ASDs.  The glass transition 
temperature (Tg) is the temperature at which an amorphous “glass” turns into a meta-stable, or 
super-cooled, liquid.  The Tg of an ASD is a function of the molecular interactions between the 
molecules.  One Tg for the solid dispersion indicates that the components are indistinguishable 
down to the 30µm scale.  If more than one Tg is observed for a solid dispersion, this indicates 
phase separation of the components in the mixture and the two Tgs correspond to the individual 
components of the phase separated dispersion. (1) Phase separation usually happens before 
nucleation and crystal growth occur for the ASD.   
 This chapter describes the characterization of ASDs of AMG 517 in HPMC-AS 
manufactured by spray drying.  The amorphous nature of the ASDs is confirmed by XRPD and 
modulated DSC.  Residual solvent is evaluated by GC and TGA and the glass transition (Tg) is 
used to evaluate the drying process and to observe trends in several lots of AMG 517 in HPMC-




Material Preparation - Spray Dry Manufacturing 
 
Ten different ASDs of AMG 517 in HPMC-AS with 0 – 100% drug loads were spray dried 
using a modified B-290 Buchi Mini Spray Dry System.  Additional ASDs of AMG 517 in PVP 
were spray dried with 30% and 80% drug load.  Manufactured ASDs were stored at 2-8 °C with 
desiccant.     
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Table 1. Spray dry manufacturing conditions for ASDs 
Parameter Condition 
Nozzle type Ultrasonic 
Inlet temperature ~75 °C 
Outlet temperature ~ 50 °C 
Drying Gas Flow ~ 0.34 kg/min 
Atomizing Gas Pressure ~70 psi 





ASDs were dissolved in DMSO at ~0.05 mg/ml concentration before being injected onto a 
C18(2) 150mm x 4.6mm x 5μm column on Agilent 1100 HPLC.  Acetonitrile-water mobile 




A Sympatec Particle Size Analyzer with HELOS/RODOS/M disperser and 4mm ASPIROS 
injector was used.  Measuring range used R3 lens (0.5/0.9µm – 175µm) and pressure conditions 
of 1bar, 30mm/sec.      
 
Scanning Electron Microscopy  
 
An XL-30 ESEM, manufactured by Philips, with Au-Pd sputter coater and 5.0 kV Beam was 
used to acquire images of spray dried ASD materials.  
 




After spray drying, each ASD was transferred to a glass dish for drying, securely covered 
with a tissue (to protect from dust and to keep the powder in the dish during drying) and placed 
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into a vacuum oven at various temperatures ranging from 40 °C to 80 °C.  After drying, material 





Samples were prepared for GC analysis at ~20 µg/ml (~20mg in 1ml DMSO) and sonicated 
for 5 – 15 minutes in a sonic bath until the solid completely dissolved in DMSO solvent.  The 
GC (Agilent 6890) system parameters are listed below. 
Table 2. Conditions for GC analysis of ethyl acetate in ASDs 
Parameter Condition 
Column 30m x 530µm x 3µm DB-624    
Temperature Ramp 40 °C to 250 °C at 15 °C/min 
Inlet Type EPC Split-Splitless 
Inlet Conditions 3.4 psi 
Helium flow 30.2 ml/min  
Split Ratio 5:1  
Detector Type FID  
H2 flow 40 ml/min 
Air flow 350 ml/min 
Makeup flow 20 ml/min 
 
TGA Method  
 
A TGA Q500 (TA Instruments) system was used with aluminum TGA pans.  A 10 °C/min 






Amorphous content was analyzed using a Phillips X’Pert X-ray Powder Diffraction 
instrument with CuKa, fixed slit lens at room temperature.   
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Table 3. Conditions for XRPD analysis of ASDs 
Parameter Conditions 
Power Settings 45kV, 40mA 
Range of detection angle 3.000 deg to 35.000 degrees 2-theta 
Steps 0.00837 degree steps at 35.56 sec/degree 
 3823 steps 
Stage revolution time 2.000 seconds/ revolution 
 
 
Modulated DSC (mDSC) 
 
A DSC Q1000 (TA Instruments) system was used with crimped aluminum DSC pans and dry 
nitrogen purge.  A heating ramp of 5 °C/min was applied from 25 °C to 250 °C with modulation 





ASD particles were immersed in Resolve Microscope Immersion Oil and observed using a 
Nikon Eclipse E600 POL microscope with cross-polarizing lens at 50X magnification.  The 
temperature was controlled with Linkam LNP TMS94 hotstage programmed with a 2°C/min 








Material Preparation - Spray drying 
 
Spray dry manufacturing results are shown in Table 4 and Table 5.  An exceptionally high 
yield was obtained due to a modification of the spray dryer system with customized glassware.  
Sufficient material was generated for use in characterization and crystallization experiments for 
ASDs of AMG 517 in HPMC-AS and AMG 517 in PVP.   
 
Table 4.  Spray dry manufacturing results for HPMC-AS ASDs. 




Yield,  % 
ASD1 0 100 3000 2100 70 
ASD9 15 85 1875 953 51 
ASD10 30 70 1875 1113 59 
ASD2 50 50 4000 2715 68 
ASD3 62 38 4000 2860 72 
ASD4 70 30 4000 2660 66 
ASD5 75 25 5500 3770 69 
ASD6 82 18 6000 4150 69 
ASD8 95 5 6250 3915 63 
ASD7 100 0 4750 2925 62 
 
 
Table 5.  Spray dry manufacturing results for PVP ASDs. 






ASD11 50 50 5000 2550 51 







HPLC Concentration Analysis 
 
Concentration analysis for ASDs shows assay recovery for all ASDs.  Most of the ASDs 
show good recovery, with only a couple exceptions.  ASD8 targeted 95% drug load in HPMC-
AS with only 86.5% drug load recovered.  ASD11 targeted 50% AMG 517 in PVP and shows 
low recovery of 33%.  It is possible that there may be significant heterogeneity in these lots, or 
that some loss of drug occurred during the spray dry manufacturing process.     
 
Table 6. HPLC Analysis for ASDs prepared by spray drying with HPMC-AS and PVP 
Sample Name Target Drug load 
(%) 
Assay Recovery  





(50% AMG 517 in HPMC-AS) 
50 54.0 
ASD3  
(62% AMG 517 in HPMC-AS) 
62 62.3 
ASD4  
(70% AMG 517 in HPMC-AS) 
70 69.4 
ASD5  
(75% AMG 517 in HPMC-AS) 
75 75.1 
ASD6  
(82% AMG 517 in HPMC-AS) 
82 81.7 
ASD7  
(100% AMG 517) 
100 99.6 
ASD8 
(95% AMG 517 in HPMC-AS) 
95 86.5 
ASD9  
(15% AMG 517 in HPMC-AS) 
15 15 
ASD10  
(30% AMG 517 in HPMC-AS) 
30 25 
ASD11  
(50% AMG 517 in PVP) 
50 33 
ASD12  





Particle Size Distribution 
 
A clear relationship between drug load and particle size exists.  Particle size trends smaller 
with higher drug load in the ASDs.  In addition, all spray dried ASDs of AMG 517 and HPMC-
AS have a d90 particle size between 15 and 40 µm with a small distribution, indicating the spray 
dry conditions used control the process reasonably well.  
 






In Figure 2 are shown images of ASDs.  Lower drug load ASD particles such as ASD2 
(50% AMG 517 in HPMC-AS) appear wrinkled (like deflated soccer balls), while higher drug 
load ASD particles such as ASD5 (75% AMG 517 in HPMC-AS) are closer to being spherical.  
It could be that the amorphous drug is stabilized by filling in the space between polymer strands.  
Crystalline AMG 517 is shown bottom left, with partially crystallized ASD shown bottom right.  
The partially crystallized ASD appears to have crystalline particles coming out of the spherical 
ASD particles and from the surface of the particles.    
 
Figure 2. SEM images of ASDs. Top left: ASD2 (50% AMG 517 in HPMC-AS). Top right: 
ASD5 (75% AMG 517 in HPMC-AS). Bottom left: Crystalline AMG 517. Bottom right: 
partially crystallized ASD6 (82% AMG 517 in HPMC-AS) after stability 60°C/75% RH.   
   
ASD6 (82% AMG 517 in HPMC-AS) 
after 60°C, 75% RH for 14 days








TGA results for ASDs after drying are shown in Table II.  The detection limit is ~ 0.05% 
weight loss.  The boiling point of ethyl acetate is 77 °C, but TGA thermograms show weight loss 
above 100 °C.  This suggests that solvent is incorporated into the ASD material lattice, not 
surface bound.  Higher drug load ASDs appear to hold the solvent in the material longer, and it is 
probable that the drug is interacting with the residual ethyl acetate solvent.  Surface bound water 
is also expected to come off ~ 100 °C, and TGA cannot distinguish between solvent weight loss 
and water weight loss.  A method specific to ethyl acetate is needed to confirm that the weight 
loss at ~ 100 °C is from residual solvent and not water.   
 
Figure 3. Residual ethyl acetate aolvent weight loss by TGA for various ASDs.  
ASD3 (62% AMG 517)  
 < 0.05% 
 
ASD4 (70% AMG 517)   
0.08% 
 
ASD5 (75% AMG 517)  
0.09% 
 
ASD6 (82% AMG 517)  
0.10% 
 





Gas Chromatography (GC) 
 
The GC method used here is specific to ethyl acetate.  GC results are compared with TGA 
and found to compare relatively well for results above 0.05%, as shown in the Table 7.  Either 
method could be used to measure residual ethyl acetate solvent in ASDs of AMG 517 in HPMC-
AS.  From the GC analysis, it is clear that the solvent loss observed by TGA is ethyl acetate, not 
water or any other solvent.  The GC method is also more sensitive than TGA below 0.05% ethyl 
acetate and should be used to quantify lower levels of ethyl acetate for ASDs of AMG 517 in 
HPMC-AS.      




Sample Name Composition % EtOAc by GC % wt loss by TGA 
ASD1 HPMC-AS only (no drug) 0.02 < 0.05 
ASD9 15% AMG 517 in HPMC-AS -- < 0.05 
ASD10 30% AMG 517 in HPMC-AS -- < 0.05 
ASD2 50% AMG 517 in HPMC-AS 0.01 < 0.05 
ASD3 62% AMG 517 in HPMC-AS 0.03 < 0.05 
ASD4 70% AMG 517 in HPMC-AS 0.08 0.08 
ASD5 75% AMG 517 in HPMC-AS 0.10 0.09 
ASD6 82% AMG 517 in HPMC-AS 0.11 0.10 
ASD8 95% AMG 517 in HPMC-AS -- 0.07 
ASD7 100% AMG 517 (no polymer) 0.17 0.17 
ASD11 50% AMG 517 in PVP -- 0.74 
ASD12 80% AMG 517in PVP -- 0.22 
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ASD11 and ASD12 are PVP ASDs.  For these, some spray dried material was set aside to 
compare with dried material of the same lots.  PVP ASDs were manufactured in methanol-
methyl acetate solvent and not analyzed by GC.  The drying time to remove residual solvent for 
PVP ASDs is longer than for HPMC-AS ASDs.  It required > 21 days to dry ASD11 to 0.74% 




Drying curves for the residual solvent drying process is illustrated in the Figure 4 below.  
Higher drug load ASDs are shown to hold onto residual solvent longer during drying.  ASD7 
(100% AMG 517) requires longer than 78 hours to dry to 0.17% ethyl acetate, while ASD1 (0% 
drug) dries to ~ 0.02% in about 30 hours.   
 
Figure 4.  Ethyl acetate residual solvent as a function of drying time for ASDs of AMG 517 in 
HPMC-AS   
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Effect of Residual Solvent on ASDs  
 
The Tg of an ASD is affected by residual solvent.  As the ASD dries, the Tg of the material 
generally increases, as illustrated in Figure below for ASD8 (95% AMG 517 in HPMC-AS).  
There is minimal change in Tg below 0.2 % residual solvent and residual solvent appears 
increasingly difficult to remove below 0.1%.  Drying below 0.2% ethyl acetate is sufficient to 
stabilize the Tg of AMG 517 in HPMC-AS ASDs for crystallization studies. 
 
 
Figure 5. Drying curves for ASD8 (95% AMG 517 in HPMC-AS).  Comparison of Residual 



















































No crystallinity is observed in the XRPD spectra for the spray dried ASDs, only broad halos 
indicating a lack of long-range order.  The detection limit for crystalline AMG 517 in HPMC-AS 
is approximately 3%.  All manufactured ASDs are initially X-ray amorphous after drying to < 
0.2% residual solvent, as discussed in the drying section above.   
Comparing the XRPD patterns for ASDs of different drug load, it appeared that the halos for 
higher drug load ASDs are higher than the halos for ASDs with lower drug load.  However, 
ASD8 (95% AMG 517 in HPMC-AS) has high drug load and discounts the idea that drug load 
alone is responsible for height of the amorphous halos.  It has been recently suggested in the 
literature that water sorption of the polymer affects the high and low angle halo. (2) Recalling 
from Table 5, ASD8 has residual ethyl acetate level of 0.07%.  Now it is seen that for this ASD 
system, the XRPD halo height trends with ethyl acetate, rather than drug load. 
 
Figure 1. XRPD analysis for spray dried ASDs of AMG 517 in HPMC-AS.  All ASDs are 





Modulated DSC (mDSC) and Hotstage 
 
The total heat flow mDSC thermogram of ASD2 (50% drug load) is shown below.  As 
indicated, the sample is amorphous solid below Tg, then the sample undergoes a slight physical 
change as a meta-stable liquid before re-crystallization and then melts to become a liquid.  The 
total heat flow curve combined with hotstage pictures gives a helpful visual illustration of the 
crystallization of an amorphous solid dispersion of AMG 517 in HPMC-AS.    
 
  
Figure 7.  Heat flow plot for ASD2 (50% AMG 517 in HPMC-AS) with images showing 
particles at different stages.   
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The Figure below shows an overlay of mDSC data for selected ASDs and physical mixtures 
of AMG 517 and HPMC-AS.  The polymer HPMC-AS has a Tg around 124.8 °C, while the drug, 
AMG 517, has a Tg around 110.6 °C.  A physical mixture of HPMC-AS and AMG 517 is 
observed to have two Tg, at 109.5 °C and 124.8 °C, indicating no interaction between the two 
components of the mixture.  Spray dried ASDs of various drug loads, however, are observed 
have only one single Tg, while the physical mixture has a separate Tg for each component.  All 
the ASDs manufactured for this study are observed to have a single Tg by mDSC analyses.    
 
 































60 80 100 120 140 160 180 200 220










Summary of mDSC Results 
Figure 5 shows modulated DSC thermal data for ASDs of varying drug load of AMG 517 in 
HPMC-AS.  Each ASD was analyzed in triplicate and error bars are shown.  The melting point 
of HPMC-AS is measured ~ 290°C and ASDs with drug load below 50% have melting point ~ 
290°C, while ASDs with drug load above 50% have Tm ranging from 217°C to 229°C.  Similar 
to a eutectic for crystalline materials, this low Tm for midrange drug load for the ASD system 














Figure 9. Summary of Modulated DSC Thermal Data for triplicate runs of ASDs of AMG 517 in 
HPMC-AS.  Glass transition temperature, Tg, delta Cp (heat capacity), Enthalpy of Relaxation 
and Melting point trends are plotted in the graph.   
  
Modulated DSC Thermal Data 
for ASDs of AMG 517 in HPMC-AS
% AMG 517





























































































Significant Tg depression is observed for ASDs compared to the Tg values predicted by the 
Gordon-Taylor equation.  An extended version of the Gordon-Taylor equation for a ternary 
system containing solvent, drug and polymer to account for the presence of additional 
components such as ethyl acetate was also described in Chapter 1.  None of the prediction 
equations account for Tg depression interactions between the ASD components.   
 
Figure 10. Gordon-Taylor predictions of glass transition compared with experimental Tg values. 
 
The Tg depression observed here indicates that the attractive forces between the drug (AMG 517) 
and the polymer (HPMC-AS) are less than the drug-drug or polymer-polymer interactions. (3) 
The molecules of the two components are forced together into one phase by the spray drying and 
the HPMC-AS provides a barrier to mobility of AMG 517, causing kinetic stabilization. 
Glass Transition Temperature
as a function of drug load
% AMG 517 in HPMC-AS
























Amorphous ASDs were manufactured by a spray drying process and residual solvent was 
dried off.  For future characterization with these ASDs, residual ethyl acetate solvent levels 
below 0.1% are considered dry.  Although solvent contributes to the depression of Tg values of 
manufactured ASDs in general, significant Tg depression is seen which is not accounted for by 
residual solvent effects.  Tg depression observed here indicates drug-polymer interactions with 
lower attractive strength than drug-drug or polymer-polymer interactions.  Further studies with 
spectroscopic methods could be performed to determine miscibility of AMG 517 in HPMC-AS 
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Solid state stability studies are traditionally performed by placing solid samples at controlled 
temperature and humidity conditions and analyzing the samples at multiple time points.  One 
drawback to this method is the labor-intensive requirements of analyzing multiple times.  
Another is the uncertainty of not knowing when the actual stability-indicating event happens.  
Stability prediction can be elusive in these situations, with results often reported in general terms 
such as “> 6 months stability”.  Isothermal microcalorimetry offers an alternative way to monitor 
the stability of solid state samples, offering continuous real-time heat flow data for a single 
sample at controlled user-specified temperature and humidity conditions.  Isothermal 
microcalorimetry is becoming a more popular technique for studying crystallization of pure 
amorphous materials.  It is proposed to explore the limits of isothermal microcalorimetry in an 
effort to better understand the behavior of ASDs.  
One challenge for analyzing the stability of ASDs is quantifying the crystallinity in ASDs, 
especially partially crystallized ASD.  The presence of polymer in significant amounts can 
interfere with the sensitivity of techniques such as XRPD.  However, SSNMR is a sensitive and 
specific technique which can distinguish between amorphous and crystalline forms of many 
drugs.  AMG 517 has a CF3 functional group which experiences different environments in the 
amorphous and crystalline states, making 19F SSNMR an ideal technique to use for crystallinity 
analysis of ASDs of AMG 517 in HPMC-AS.   
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In this chapter, the crystallization of ASDs of AMG 517 in HPMC-AS is evaluated by 
traditional solid state stability method and by isothermal microcalorimetry.  The crystallinity of 
the stability samples is determined by 19F SSNMR.  Rate constants are calculated using Avrami 
kinetics and statistical predictions are made using JMP design software.  In addition, ASDs of 
AMG 517 in PVP are also evaluated by isothermal microcalorimetry to evaluate the effect of 






A 2277 Thermal Analysis Monitor (TAM) isothermal microcalorimeter was used to monitor 
the crystallization of ASDs of AMG 517 and HPMC-AS at various accelerated stability 
conditions of temperature and relative humidity.  Temperature was controlled using the TAM 
water bath.  Salt solution hygrostats were used to control the relative humidity in each sample 
cell.  After stabilizing the TAM water bath at the desired experimental temperature, each channel 
was calibrated prior to beginning the crystallization experiments.  Between 30 – 150mg of ASD 
sample was placed into a stainless steel ampoule and hygrostat vials containing appropriate 
saturated salt solutions were used to control relative humidity inside the ampoule.  Reference 
ampoules either contained reference material and a hygrostat or were left empty.  The sample 
ampoule and reference ampoule for each experiment were simultaneously lowered into the 
“equilibration position” and held in that position for ~30 minutes to equilibrate before being 
moved to the sample position to monitor the crystallization reaction.  Experiments were 
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continued until the crystallization event was completed, or 42 days, whichever was shorter.  




Conditions used for TAM crystallization were chosen to cover a range of possible 
crystallization rates, using 3 variables: polymer (or drug load), temperature and relative humidity 
(RH), as illustrated in Box 1.  The drug load range is 50 – 100%, temperature range is 50 – 80°C, 
and RH ranges between 10% – 75%.  The temperature and RH range was chosen based on 
conditions required to sustain the ASDs at or below the predicted Tg value during the 
experiments.  TAM crystallization conditions used are indicated in Figure 1, and also listed in 
Table 1 and Table 2.  
 
Figure 1 – Box representation of Conditions for TAM Crystallization Experiments.  Red circles 
represent AMG 517 in HPMC-AS, blue circles represent AMG 517 in PVP and green circles 
represent 100% AMG 517.   
 
Red – AMG 517 in HPMC-AS  
Blue – AMG 517 in PVP 
Green – 100% AMG 517 
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Table 1.  TAM Crystallization Experimental Information for HPMC-AS ASDs 
Sample Information TAM Condition Information 
ASD name Drug load 
(% AMG 517) 
Temperature (°C) Relative Humidity (%) Salt Solution 
ASD2 5075 50 50 75 NaCl 
ASD2 8025 50 80 25 MgCl2 
ASD2 8075 50 80 75 NaCl 
ASD3 6550 62 65 50 NaBr 
ASD3 8075 62 80 75 NaCl 
ASD4 6550 70 65 50 NaBr 
ASD5 6550 75 65 50 NaBr 
ASD6 5025 82 50 25 MgCl2 
ASD6 5075 82 50 75 NaCl 
ASD6 6550 82 65 50 NaBr 
ASD6 8025 82 80 25 MgCl2 
ASD6 8050 82 80 50 NaBr 
ASD6 8075 82 80 75 NaCl 
ASD8 6575 86 65 75 NaCl 
ASD7 5050 100 50 50 NaBr 
ASD7 5075 100 50 75 NaCl 
ASD7 6510 100 65 10 LiCl 
ASD7 6525 100 65 25 MgCl2 
ASD7 6550 100 65 50 NaBr 
ASD7 6575 100 65 75 NaCl 
ASD7 8025 100 80 25 MgCl2 
 
 
Table 2.  TAM Crystallization Experiment Information for PVP ASDs 
Sample Information TAM Condition Information 
Sample name Drug load 
(% AMG 517) 
% EtOAc Temp (°C) % RH Salt Solution 
ASD11 5075 33 Not Dry 50 75 NaCl 
ASD11 5075 33 Dry 50 75 NaCl 
ASD11 6575 33  65 75 NaCl 
ASD11 8075 33 Not Dry 80 75 NaCl 
ASD11 8075 33 Dry 80 75 NaCl 
ASD12 5075 80  50 75 NaCl 
ASD12 8050 80  80 50 NaBr 
ASD12 8075 80 Not Dry 80 75 NaCl 




Vapor sorption (DVS)  
 
Vapor sorption experiments are used to predict the Tg of each ASD at the experimental 
conditions.  The amount of water taken up at a given RH is determined from water uptake 
isotherms for ASDs at 25°C, 40°C, 50°C and 60°C.  Using water uptake isotherms for an ASD at 
several temperatures, the “Water Uptake vs. Temperature” curve can be generated for a given 
RH.  Using the water uptake value at a specific set of temperature and RH conditions and 
applying the Gordon-Taylor equation, the Tg of the sample at those conditions can be predicted.  
Water vapor sorption experiments were run at conditions listed in Table 3 below.   
 
Table 3. Vapor sorption Conditions 
Vapor Sorption Instrument DVS Advantage 1 (Surface Measurement Systems) 
Temperature 25°C, 40°C, 50°C, 60°C 
Cycle details 0 - 90 - 0% RH, 10% RH steps, one full cycle 
 0.003% dmdt (change in mass per minute), 3 hr max per step 




Traditional Solid State Stability 
 
To compare with TAM crystallization studies, a series of “traditional” solid state stability 
experiments were set up, using ASD samples of drug load between 50 and 100% AMG 517 in 
HPMC-AS were placed on stability at four different conditions (25°C/60% RH,  40°C/75% RH, 
60°C/30% RH and 60°C/75% RH).  Sealed jars containing saturated salt solutions were used for 
60°C/30% RH and 60°C/75% RH conditions, while electronically controlled humidity chambers 
were used for 25°C/60% RH and 40°C/75% RH conditions.  Crystallinity was evaluated by 
XRPD and/or mDSC at appropriate time points ranging from 0 to 19 months, using the same 
XRD and mDSC methods described in Chapter 3.  Samples were removed from the stability 
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condition when >10% crystallization was observed by XRD and stored at 4°C under desiccation.  
SSNMR was used to measure crystallinity after the final time point.  Figure 2 shows a box 




Figure 2 – Box representation of Solid State Conditions.  Red circles represent conditions used 




Red – AMG 517 in HPMC-AS  
Purple – 100% AMG 517 
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Crystallinity by SSNMR  
 
 
All SSNMR measurements were conducted using a Bruker DSX spectrometer operating at a 
1H resonance frequency of 600MHz. A Bruker 2.5-mm double resonance magic angle spinning 
(MAS) probe head was used to record all NMR data. 19F SSNMR spectra were recorded using 
routine one pulse sequence with sample spinning at 30 kHz. 8 scans were collected for each 
sample for signal to noise averaging.  A recycle delay of 20 seconds was used for all samples. 
Natural abundance teflon with the fluorine peak at 146.89ppm was used as the chemical shift 
reference.   
19F SSNMR is used to quantify the % crystallinity for samples crystallized by TAM or 
traditional solid state stability.  Pure amorphous and pure crystalline AMG 517 samples are used 
as reference materials.  The % crystalline AMG 517 in each ASD crystallization sample is 
determined using de-convolution software from Mestrenova.   
 
 Crystallization Kinetics 
 
Avrami rate constants are calculated for each TAM crystallization sample, using rate data 
from the TAM where possible.  For experiments where complete crystallization rate data from 
TAM was not possible, rate constants were estimated using a single end point by estimating n=2, 
with crystallization times from the end of the TAM experiment and % crystallinity from 19F 
SSNMR measurements associated with the endpoint of the TAM experiment.  Based on the rate 
constant values, trends were observed for relative humidity and temperature.  In addition, it was 
shown that a log plot of rate constants against drug load could be used to aid selection of drug 








The results from water vapor sorption experiments used to predict Tg at crystallization 
conditions are shown in the Tables below for ASD6 (82% AMG 517 in HPMC-AS).  Table 4 
shows the % water uptake data for ASD6 (82% drug load) at various temperatures and RH 
conditions.   
Table 4.  Vapor Sorption Data for ASD6 (82% drug load), showing % water uptake at various 
temperature and RH conditions. 
DVS 


















25 0.417 104.1 0.699 101.5 0.874 99.9 0.949 99.3 
40 0.46 103.7 0.717 101.3 0.913 99.5 1.002 99.0 
50 0.487 103.4 0.797 100.6 0.989 98.9 1.08 98.5 
60 0.662 101.8 1.016 98.6 1.271 96.4 1.401 95.9 
80 1.203* 97.0 -- -- -- -- 2.43* 86.4 
*These water uptake values are taken from the extrapolated lines for the fitted RH curves. 
 
The data are plotted in Figure 1 to show % Water uptake vs. Temperature.  Extrapolating 
from the lines, according to the fitted equations, it can be roughly predicted what the water 
uptake would be at higher temperatures.  For example, at 80°C/75%RH, the predicted water 
uptake is approximately 2.4%.  The Gordon-Taylor equation (1) predicts ASD6 (82% AMG 517 
in HPMC-AS) with 2.4% water to have Tg of approximately 86°C, as indicated in Table 4.   
This result suggests that a condition of 80°C/75%RH borders the Tg for ASD6 (82% AMG 
517 in HPMC-AS).  It is expected that crystallization would occur rapidly above this condition 
and be significantly slower below this condition.  All the other conditions tested for TAM 
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crystallization have water uptake that predicts Tg well above the experimental conditions.  An 
important question for ASDs is whether crystallization progresses at conditions below Tg as has 
been suggested previously. (2) Analysis of ASDs by TAM crystallization experiments below Tg 
can help answer this question for the ASD system of AMG 517 in HPMC-AS. 
 
Figure 3.  Effect of Temperature on Water Uptake for 82% AMG 517 in HPMC-AS. 
 
The equations shown here are fitted to the data using Excel software.  It is unknown what the 
parameters of the fitted equations correspond to, but the fitting is still useful in determining an 
approximation of water uptake for Tg predictions which are used to choose relevant 







A TAM plot for ASD7 (100% AMG 517) at 65°C, 25%RH is shown in Figure 2.  The heat 
flow-time curve is shown.  At the beginning of the experiment, a short equilibrium is observed, 
as the temperature of the sample/ampoule is stabilizing with respect to the temperature of the 
TAM bath.  This equilibrium process can take up to several hours, depending on how much pre-
equilibration is done prior to the start of the experiment.   
  
Figure 4. Illustration of the integration for ASD2 (50% AMG 517) at 80°C/75%RH.  
The area under the curve is integrated (2.9587 J) and divided by the sample weight (150 mg).  
Heat of crystallization for this sample is ∆Hc = 39.6 J/g, after adjustment for drug load. 
 
 The TAM plot in Figure 4 shows the heat flow- time curve.  A positive heat flow 
indicates that energy is released during the thermal event.  The start of the peak indicates the 
induction time, while the end of the peak is "t", the time to crystallization.  The area under the 




Heat of crystallization, ∆Hc, is calculated for the crystallization peaks by integrating the area 
under the curve and dividing by the sample weight, as illustrated in Figure 2.   
If crystallization is the only heat event happening during the experiment, then analysis is 
straightforward.  However, the TAM is sensitive to very small temperature changes and will pick 
up thermal events such as crystallization, evaporation and condensation as deviations from zero 
baselines.  The TAM does not differentiate between different types of thermal events and 
thermal events may overlap if they happen simultaneously, so results can be difficult to interpret 
if multiple events are happening in the experimental environment.   
Due to the sensitivity of the microcalorimeter, an equilibration event is observed at the 
beginning of the experiment for all of the TAM plots.  This is primarily because the temperature 
of the ampoules is not completely equilibrated with the temperature of the microcalorimeter bath.  
In some instances, the hygrostat also takes time to equilibrate with the sample inside the ampoule 
at the experimental temperature and this evaporation/condensation process can extend the 
apparent equilibration time beyond the first couple hours of the experiment.  This was observed 
in several of the experiments at 25%RH, rendering much of the 25%RH ASD data unusable for 
observing crystallization.  The samples are typically placed in the “equilibration position” to 
hasten temperature equilibration before being lowered into the sample position.  Extended 
equilibration of the sample prior to the start of the experiment can risk missing part of the 
crystallization event.  In some cases, the crystallization event may begin before the system has 





TAM Noise and Detection Limits 
The TAM noise specifications are +/- 20 nW for an empty 4mL channel.  The detection limit 
is typically considered to be 3 – 5 times the signal-to-noise ratio for an analytical method.  Based 
on this criteria, the detection limit for this method is < 100nW (or 0.1 μW).   
 
Figure 5. ASD7 (100% AMG 517) at 50°C/75% RH compared with ASD3 (62% AMG 517 in 
HPMC-AS) at 65°C/50%RH.   
 
A comparison of the baselines for ASD7 at 50°C/75%RH and ASD3 at 65°C/50%RH is 
shown in Figure 5.  A clear crystallization event is observed for ASD7 (100% AMG 517) at 
50°C/75%RH, with low power over several weeks.  The crystallization for ASD3 (62% AMG 
517 in HPMC-AS) is so slow that little change is detected over several weeks.  The response is 
slightly higher than the detection limit for the instrument, indicating there may be some real heat 




Crystallizations with 100% ASD (No Polymer) 
Crystallization of amorphous spray dried drug (100% drug load) was evaluated.  Clear 
crystallization events were observed for spray dried 100% AMG 517 at several of the 
crystallization conditions chosen in the experimental design.  Crystallinity analysis with 19F 
SSNMR after the TAM experiments confirms that each of the 100% AMG 517 samples 
crystallized completely during the TAM experiments.   
 
Effect of Relative Humidity 
An overlay of ASD7 (100% DL) at 65°C/10%RH, 65°C/25%RH and 65°C/75%RH is shown 
in Figure 6.  As expected, crystallization proceeds faster with higher humidity conditions for 
samples run at the same temperature.  The peaks generated from fast crystallizations are higher 
and sharper, and the peaks for slower crystallizations are lower and broader.  The crystallization 
at 65°C/10%RH proceeds so slowly that it requires 42 days to complete and when plotted on the 
same scale as the faster crystallizations, the “peak” is barely apparent.   
For the slow crystallization at 65°C/10% RH in Figure 4, there is a significant rise and fall in 









Figure 6.  Effect of relative humidity (RH) on crystallization rate for ASD7 (100% DL).  Higher 
RH increases crystallization rate for samples at the same temperature.  At conditions of 
65°C/10%RH (blue), slow crystallization occurs over 42 days and the peak is barely detected in 
this experiment.  Crystallinity was confirmed at the end of the experiment for each sample.  
Enthalpy of crystallization, ΔHc, values are 26.3, 39.4 and 41.3 J/g, for 10%RH, 25%RH and 




       
Effect of Temperature 
 
Temperature also has a significant effect on the crystallization rate of spray-dried AMG 
517, as shown by the TAM experiments at 25%RH.  An overlay of ASD7 (100% DL) 
80°C/25%RH (red) with 65°C/25%RH (green) is shown in Figure 7.  Higher temperature 
increases crystallization rate, with the 80°C experiment completing crystallization in less than 2 
days and the same sample at 65°C takes about 5 days to complete the crystallization.   
 
Figure 7. Effect of temperature on crystallization rate of 100% AMG 517 at 25%RH.  Higher 
temperature increases crystallization rate. Crystallinity was confirmed at the end of the 
experiment for each sample.  Integrated areas under the peaks for each sample yield enthalpy of 





At 75%RH the same temperature trend is observed, with higher temperature causing much 
faster crystallization, as shown in Figure 5.  At 50°C/75%RH, a slow crystallization is observed 
by TAM, with a slow crystallization event completing in about 33 days.   
It is interesting to note that the heat of crystallization, ΔHc, for 100% AMG 517 is found to 
be ~ 40 J/g for most conditions.  The total heat of crystallization is expected to remain the same 
for the same material.  However, less stressful experimental conditions appear to not only slow 
down the rate of crystallization, but also reduce the crystallization energy.  This may suggest an 
issue with using the TAM to detect low levels of heat flow over long experimental times, but 
could also indicate a real change in crystallization mechanism at milder conditions.   
 
Overall, the experiments with 100% AMG 517 show that crystallization events can be 
detected by TAM at elevated temperature and RH, if the crystallization rate is fast enough to 
complete within six weeks.  In general, the expected trend of increased crystallization rate with 
increased temperature and relative humidity is confirmed.  As the crystallization rate decreases, 
the observed crystallization peaks broaden and shorten.  At lower temperature and relative 
humidity conditions, very slow crystallization is observed to occur over a period of days to 
weeks.   
 
 
Crystallizations with HPMC-AS ASDs 
 
ASDs have been reported to inhibit crystallization of certain drugs, including AMG 517. (3) 
The TAM crystallization experiments clearly show this to be the case for ASDs of AMG 517 in 
HPMC-AS.  The trends and insights gained from observing the crystallization of ASDs of AMG 
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517 in HPMC-AS with TAM at different conditions are discussed.  19F SSNMR crystallization 
analysis confirms the partial crystallization of ASD samples at most conditions (data shown in 
Table 7).   
The highlighted region for Figure 8 displays the low level signals for the very slow reactions 
of ASDs at 65°C/50%RH, where the pure drug crystallized completely in less than 7 days.  At a 
glance, the TAM experiment does not appear to be able to detect such slow crystallizations, but it 
is more instructive to consider detection limits.  The detection limit of the instrument is < 0.1 
μW.  For these experiments, the signal noise is ~ 150 - 200 nW which is higher than the 
detection limit and supports the proposal that some real heat signal is being observed.  It is 
possible that some of the apparent “noise” in these TAM plots has buried in it low levels of heat 
change associated with crystallization for these samples.  However, the process is so slow that, 
for practical purposes, no clear crystallization can be defined for these ASD samples at these 
conditions.   
For each ASD at 65°C/50%RH, no crystallization peaks are defined by the TAM.  However, 
each of the ASD samples in Figure 8 has between 5 – 10% crystalline as measured by 19F 
SSNMR.  This means that there is a very slow crystallization taking place which only begins to 
crystallize within the 6 week experimental timeframe and is not energetic enough to be detected 









Figure 8. Effect of Drug load on Crystallization Rate of AMG 517 in HPMC-AS at 







Effect of Temperature, Humidity and Drug load on ASD Crystallization 
Due to the slow crystallization of ASDs compared to drug-only samples, good crystallization 
data was rare for ASDs.  The presence of polymer makes a big difference in slowing the 
crystallization rate.  As long as some polymer is present, the crystallization is significantly 
slower; the amount of polymer in the ASD is less important than the effect of temperature and 
relative humidity.  HPMC-AS inhibits crystallization, but if the experimental conditions are 
stressful enough, the ASDs will crystallize.   
An overlay of showing the effect of relative humidity on ASD crystallization rate is shown in 
Figure 9.  An overlay of  ASD6 (82% AMG 517 in HPMC-AS) at 50°C/75%RH, 65°C/75%RH 
and 80°C/75%RH is shown in Figure 10.  Similar to the trends seen for the pure drug, 
crystallization proceeds faster with higher humidity and higher temperature conditions for 
samples run at the same temperature.  The energy associated with the crystallization is much 
slower for ASDs, although the general trends are similar.  The only conditions that show a clear 
crystallization event for 82% AMG 517 in HPMC-AS is at 80°C/75%RH.  For the lower 
conditions, crystallization of the ASDs proceeds so slowly that it requires >>42 days to complete 
and the crystallization plot from the TAM does not provide useful rate data.   
 The effect of drug load on crystallization rate is shown in Figure 11 for conditions of 
80°C/75% RH with drug load of 50%, 62% and 82% AMG 517 in HPMC-AS.  All three ASDs 





Figure 9. Effect of Relative Humidity on the Crystallization Rate of ASD6 (82% AMG 517 in 
HPMC-AS).  At 80°C/75%RH causes crystallization, but 50%RH does not provide clear 





Figure 10. Effect of Temperature on the Crystallization Rate of ASD6 (82% AMG 517 in 
HPMC-AS).  At 75%RH, 80°C causes crystallization, but 65°C and 50°C does not appear to 






Figure 11. Effect of drug load on crystallization for ASDs of AMG 517 in HPMC-AS at 
80°C/75% RH.  At first glance, drug load does not appear to significantly affect the 




Looking more closely at the TAM profile at 80°C/75%RH from Figure 11, there appears to 
be two distinct crystallization events happening for the 82% drug load sample.  As drug load 
decreases to 62% AMG 517 in HPMC-AS, the two events run together and at 50% AMG 517 in 
HPMC-AS, the early event appears to be absent and only the main crystallization event is 
apparent.  This drug load dependent behavior suggests a phase separation that was not 
observable by mDSC.  If the super-saturation level of the ASD system is around 50%, the first 
crystallization event corresponds to a drug-rich domain, with the second event corresponding to a 
more intimately mixed domain.   
After the TAM experiments, each sample was analyzed for crystallinity by 19F SSNMR.  One 
surprising result from 19F SSNMR data is that ASDs do not appear to crystallize completely – 
there is a mixture of amorphous and crystalline drug in the “crystallized” ASD.  Not all the drug 
in the ASD crystallizes during the crystallization event.  This suggests that a third domain may 
exist.  It could be imagined that very small drug domains exist and are bound up in the polymer 
such that they cannot nucleate to initiate crystallization.  From the 19F SSNMR, it is measured 
that ~60-80% of the drug in each ASD is crystallizing at 80°C/75%RH leaving ~ 20 – 40% of the 










Summary of Crystallization Data for ASDs of AMG 517 in HPMC-AS 
A summary of all the crystallization data is available in Table 5.  Although the TAM plots for 
ASD samples are not as clean as the 100% drug data, ASDs display the same general 
temperature and humidity trends as drug-only samples and some important insights can be 
gained from the ASD crystallization data.  First, in terms of predicting the crystallization time, 
the amount of ASD in the sample appears to matter less than the conditions used.  That is, a 
small amount of polymer added to the pure drug has a dramatic effect. The presence of HPMC-
AS with AMG 517 causes slower crystallization compared with pure drug.   
Second, the crystallization rates of ASDs are slower than drug alone, but the temperature and 
relative humidity trends are shown to be the same.  Like the 100% AMG 517 (pure drug) 
samples, ASDs with polymer also crystallize faster with higher temperature and humidity 
conditions.  This is basically a Tg effect – the closer the conditions are to the Tg, the faster the 
crystallization progresses.  The ASD conditions which show clear crystallization of the drug in 
polymer have predicted Tg values right at the experimental conditions.   
Third, the polymer system does a good job of stabilizing the drug against rapid 
crystallization, but the crystallization still happens.  The crystallization event for ASDs may take 
days, weeks or longer to complete and may not be observable even with sensitive isothermal 
microcalorimetry methods, but other methods such as SSNMR show the crystallization is still 
occurring.  Even at less stressful conditions, slow crystallization is still observed.  This finding is 
consistent with the Tg depression observed.  Sometimes the slow crystallization is virtually 
undetectable by TAM experiments and there may be several different factors influencing the rate 
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and extent of crystallization.  For such slow crystallizations, orthogonal methods of assessing 
crystallization (such as SSNMR) can be useful in determining crystallization rates.   
Fourth, the TAM profiles indicate a drug load-dependent phase separation for ASDs, causing 
distinct crystallization events which may be the result of drug-rich domains existing above the 
miscibility of the AMG 517 in HPMC-AS.  The drug-rich domains could account for the 
relatively fast first crystallization event for higher drug load ASDs.  In addition, the incomplete 
crystallization of ASDs suggests a third phase which is stuck in the polymer and doesn’t 
crystallize at all.   
Finally, the crystallization enthalpy, ∆Hc, is approximately 40 J/g for pure spray dried AMG 
517, and approximately 20 J/g for ASDs of HPMC-AS.  The measured crystallization enthalpy 
for ASDs is approximately half that of pure drug samples.   
 
TAM Crystallizations with PVP ASDs 
Polymer type and residual solvent content also affect the crystallization of ASDs.  Two 
additional ASDs at 80% AMG 517 and 33% AMG 517 were prepared using PVP as the polymer 









Effect of Polymer on Crystallization of AMG 517  
Figure 12 shows a comparison of ASD12 (80% AMG 517 in PVP) with ASD6 (82% AMG 
517 in HPMC-AS) with the PVP ASD having faster crystallization than the HPMC-AS ASD, 
suggesting that HPMC-AS may stabilize the drug more than PVP.  A possible cause for this is 
that PVP sorbs much more water than HPMC-AS, and the Tg of PVP ASDs due to water uptake 
is predicted to be lower than HPMC-AS ASDs at the same conditions.  
 
Figure 12. Effect of polymer type on crystallization of AMG 517 at 80% drug load.  An overlay 
of 80% AMG 517 in PVP with 82% AMG 517 in HPMC-AS at 80°C/75%RH indicates that PVP 






Effect of Residual Solvent on Crystallization Rate 
Figure 13 shows an overlay of ASD11 (33% AMG 517 in PVP) with dried and non-dried 
samples at conditions of 80°C/75%RH.  Comparison of dried and non-dried PVP ASDs shows a 
faster crystallization rate for the non-dried sample.  19F SSNMR data indicates the dried PVP 
ASD (gray line) crystallizes more of the drug than the non-dried PVP ASD (pink line).  The 
crystallization enthalpy, ∆Hc, values are 19.0 J/g for non-dried ASD11 (33% AMG 517 in PVP) 
and 19.7 J/g for dried ASD11 (33% AMG 517 in PVP).   
 
 






Summary of Effects of Polymer on Crystallization 
Overall, the PVP ASDs behave similarly to HPMC-AS ASDs, with PVP ASDs having faster 
crystallization times at 80°C/75%RH condition possibly due to less complete drying of residual 
solvent.  The crystallization of AMG 517 appears to be affected by polymer choice in other 
ways.  The starting material form is consistently recovered for HPMC-AS ASDs.  However, the 
form of AMG 517 crystallizing out of the ASD is not the same form as what is recovered from 
HPMC-AS ASDs.  As indicated in Table 7, for ASD11 (33% AMG 517 in PVP) and ASD12 
(80% AMG 517 in PVP), a different form was recovered after the TAM crystallizations.  The 
higher Tg suggests this could be a more stable form, possibly an EtOAc solvate.   
 
 Residual solvent level differences are more pronounced for ASD11 (33% AMG 517 in PVP) 
and ASD12 (80% AMG 517 in PVP) and TAM experiments comparing dried and non-dried 
samples are listed in Table 7.  For ASD11 (33% AMG 517 in PVP) at 80°C/75%RH experiments 
comparing 0.71% ethyl acetate and 3.81% ethyl acetate, there is a clear difference between dried 
and non-dried materials.  Crystallization begins sooner and proceeds faster with a higher level of 
ethyl acetate.  However, a lower ∆Hc and lower % crystallinity for non-dried samples indicates 
that the residual solvent may inhibit completion of the crystallization process.   
 
Figure 14 shows the relative crystallization time for each TAM experimental condition, with 
longer times indicated by larger circles.  Unexpectedly, most of the ASDs at conditions below 
80°C/75%RH required crystallization times longer than 42 days to complete crystallization, so 
the samples were taken down and evaluated as partially crystallized materials after 42 days.  The 
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slow crystallization of AMG 517 in ASDs shows that polymer does kinetically stabilize the 
amorphous drug against crystallization, with both HPMC-AS and PVP.    
 
 
Figure 14 – Box representation of Crystallization Time. Crystallization time is indicated for each 
crystallization condition used for TAM experiments.  Circle size indicates length of time (i.e. 




Red – AMG 517 in HPMC-AS  
Blue – AMG 517 in PVP 
Purple – 100% AMG 517 
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Table 5.  Summary of TAM crystallization data.  Basic solid state characterization was 
performed on all TAM crystallization samples when the TAM experiments were finished.  XRD 
and mDSC were inspected to verify the form of crystallized AMG 517 material.   
Sample Information TAM Crystallization 
Data 
 mDSC 



















ASD2 5075 54 50 75 0.01 5.0 33.2 0 <3 104.3 
ASD2 8025 54 80 25 0.01 2.2 42 0 3-10 103.5 
ASD2 8075 54 80 75 0.01 0.729 12.9 39.4 >>17 99.5 
ASD3 6550 62 65 50 0.03 4 42 0.54 <3 105.3 
ASD3 8075 62 80 75 0.03 0.25 13.8 31.9 >>17 105.2 
ASD4 6550-1 70 65 50 0.08 2 34 0 <3 106.7 
ASD4 6550-2 70 65 50 0.08 6.5 42 0 <3 108.2 
ASD5 6550-1 75 65 50 0.10 5 22.8 0 <3 106.7 
ASD5 6550-2 75 65 50 0.10 15 42 0 <3 108.8 
ASD6 5075 82 50 75 0.11 25 33.1 0 <3 107.5 
ASD6 6550 82 65 50 0.11 2.8 42  3-10 108.7 
ASD6 8025 82 80 25 0.11 8.6 42 0 17 105.4 
ASD6 8050 82 80 50 0.11 4 40.7 12.6 >17 102.7 
ASD6 8075 82 80 75 0.11 3.5 11 37.9 100        na 
ASD8 6575 95 65 75 0.08 0.62 15.5 11.7 100 109.3 
ASD7 5050 100 50 50 0.19 22.8 37.8 0 >17 108.8 
ASD7 5075 100 50 75 0.19 2.7 33.2 23.0 100 na 
ASD7 6510 100 65 10 0.19 3.5 40.9 26.3 100 Tm 229C 
ASD7 6525 100 65 25 0.19 0.25 6.5 39.4 100 Tm 229.3 
ASD7 6550 100 65 50 0.19 0.69 6.75 42.9 100 Tm 229C 
ASD7 6575 100 65 75 0.19 0.15 3.75 41.3 100 Tm 229.2 
ASD7 8025 100 80 25 0.19 0.17 2.3 43.3 100 107.4 
ASD11 5075d 33 50 75 0.74 12 42 0 <3 116.3 
ASD11 5075nd 33 50 75 3.81 18 42 0 <3 141.5 
ASD11 6575nd 33 65 75 3.81 2.0 19.7 182 New 165 
ASD11 8075d 33 80 75 0.71 7 42 108 New Unclear 
ASD11 8075nd 33 80 75 3.81 2.5 20.9 95 New Unclear 
ASD12 5075nd 80 50 75 2.11 10 42 0 New 140.6 
ASD12 8050nd 80 80 50 2.11 10 42 0 <3 117.6 
ASD12 8075d 80 80 75 0.22 1.8 9.3 26.0 100 180 
ASD12 8075nd 80 80 75 2.11 1.0 9.0 19.9 100 na 




Solid State Stability Results 
 
Results of traditional solid state stability experiments show similar (and expected) trends 
compared to those discussed from TAM experiments.  Crystallization is faster with higher 
temperature and higher humidity.  XRPD is used to determine when the sample reaches >10% 
crystalline and removed from stability condition at that time.  For some of the ASDs, 19 months 
on condition still shows < 3% crystallinity by XRPD and stability is reported as > 19 months.   
At 60°C/30%RH condition, the samples were found to be damp the 12 week time point and 
XRPD showed  >>17% crystallinity.  The samples crystallized sometime between 9 weeks and 
12 weeks and the 10% crystallization point was missed, most likely due to condensed water from 
hygrostats in the controlled humidity jars causing crystallization.     
 
Figure 15 – Box representation of experiment end times for traditional solid state stability. Circle 
size indicates length of time (i.e. larger circles required longer time to crystallization).   
Red – AMG 517 in HPMC-AS  




XRPD for ASDs after storage at various conditions shows crystalline AMG 517 forming 
from the ASDs.  Physical mixtures containing 3%, 10% and 17% crystalline AMG 517 are used 
as references to compare with stability samples. 
 
Figure 16.  Crystallinity analysis of ASD6 (82% AMG 517 in HPMC-AS) by XRPD after 
storage at 25°C/60%RH for 19 months, 40°C/75%RH for 19months and 60°C/30%RH for 12 
weeks.    
 
XRPD for PVP ASDs indicate that a different form of AMG 517 crystallizes out of PVP 
ASDs at elevated temperature and humidity conditions.   
    
Figure 17. XRPD spectrum for crystallized ASD12(80% AMG 517 in PVP) overlaid with 
crystalline AMG 517.  The form of the crystallized AMG 517 is different from the starting form.   
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Figure 18 shows an example of the mDSC data obtained for ASDs after stability at 
various conditions.  ASD6 (82% AMG 517 in HPMC-AS) does not indicate a phase separation 
after storage at 25°C, 60%RH for 19 months.  However, the 19F SSNMR indicates 6.1% 
crystallinity after storage at these conditions.  Even as the AMG 517 begins to crystallize out of 
the ASD, a single Tg is observed by mDSC.  Another technique would most likely be needed to 
determine phase separation for the partially crystallized samples.   
 
Figure 18.  Modulated DSC heat flow curves for ASD6 (82% AMG 517 in HPMC-AS) with less 
than 10% crystallinity after storage at 25°C/60%RH for 19 months.  A single Tg is observed in 
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Table 6 shows the solid state data for all the stability samples.  XRPD indicates whether the 
crystallinity is < 3%, 3-10%, 10-17% or >17% crystalline AMG 517.  Modulated DSC Tg values 
are listed.  The % crystalline AMG 517 in each ASD sample is determined from 19F SSNMR 
measurements at the end of the study.  Avrami rate constants, calculated as described in the next 
section, are listed.  The time required to reach a detectable level of crystallinity in the ASD 
sample by XRPD is indicated in the “Time to >10% X” column.   
 
Table 6.  Solid State Data for Traditional Stability Studies of ASDs of AMG 517 in HPMC-AS  
Sample Information   19F SSNMR   
ASD % Drug 
Load 




ASD2 54 25°C/60%RH <3 104.2 0 19mo 0 
  40°C/75%RH <3 104 6.3 19mo 2.00283e-7 
  60°C/30%RH >>17 103 80.9 12wk 0.00023462 
  60°C/75%RH ~10 102.8 13.0 12wk 1.97367e-5 
ASD3 62 25°C/60%RH <3 104.6 0 19mo 0 
  40°C/75%RH <3 104.2 4.1 19mo 1.28853e-7 
  60°C/30%RH >>17 114.8 74.4 12wk 0.00019311 
  60°C/75%RH 10-17 105.4 8.1 28d 0.00010774 
ASD4 70 25°C/60%RH <3 106.8 2.5 19mo 7.79249e-8 
  40°C/75%RH <3 104.6 5.2 19mo 1.64361e-7 
  60°C/30%RH >>17 116 60.9 12wk 0.00013309 
  60°C/75%RH >17 105.4 10.7 28d 0.00014435 
ASD5 75 25°C/60%RH <3 107.1 0 19mo 0 
  40°C/75%RH <3 106.9 4.1 19mo 1.28853e-7 
  60°C/30%RH >>17 101.4 59.8 12wk 0.00012915 
  60°C/75%RH 10-17 107 11.0 28d 0.00014864 
ASD6 82 25°C/60%RH <3 109.3 6.1 19mo 1.93721e-7 
  40°C/75%RH 10-17 109 9.5 19mo 3.07234e-7 
  60°C/30%RH 100 102.8 40.2 12wk 0.00007287 
  60°C/75%RH ~10-17 107.1 10.7 14d 0.00057739 
ASD7 100 25°C/60%RH 10-17 110.9 5.8 6mo 1.84414e-6 
  40°C/75%RH 3-10 111.3 10.6 4wk 0.00014292 
  60°C/30%RH 100 111.6 68.6 7d 0.02364005 
  60°C/75%RH 100 NA 100 7d 0.09398307 
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Figure 19 shows a box representation of the crystallization conditions again, this time with 
circle size indicating larger values for Avrami rate constants for each condition, meaning faster 
crystallization of AMG 517 from ASD for conditions with larger circles.   
 
Figure 19 – Box representation of rate constants for traditional solid state stability experiments.  




Crystallinity by SSNMR 
 
19F SSNMR is used to determine the amount of crystalline versus amorphous for each ASD 
sample.  SSNMR is an accurate assessment of the crystallinity of these samples, but only 
practical to analyze at the end, after the sample has been taken down from the accelerated 
stability condition.  A spectrum of pure crystalline AMG 517 is shown in blue in Figure 20 
overlaid with a spectrum of pure amorphous ASD7 (100% AMG 517) shown in red.  The 
observed crystalline form of AMG 517 has two molecules per unit cell, and two peaks are seen 
in the crystalline spectrum.  The amorphous peak and the second crystalline peak have 
overlapping chemical shifts, enabling distinction between the amorphous and crystalline forms.  
The detection limit of ~3% crystalline AMG 517 in amorphous or ASD material is achieved.   
 
Figure 20. 19F SSNMR spectra for amorphous AMG 517 (red) and crystalline AMG 517 (blue).  
There is some overlap in the spectra for the different forms, but also a clear distinction, which 
allows for quantification of the crystalline content in a mixture.    
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An example of 19F SSNMR spectra for a partially crystallized ASD is shown in Figure 21 
below.  In this example for ASD6 (82% AMG 517 in HPMC-AS) at 80°C/75%RH, the 
amorphous peak is overlapping with the second crystalline peak.  The signals for the amorphous 
and crystalline forms in the material can be de-convoluted using Mestrenova software and the 
percent crystallinity is calculated based on the de-convoluted areas of the peaks.  The integrated 
areas for the three peaks (two crystalline and one amorphous) are indicated in the box.   
 
Figure 21.  Deconvolution using MNOVA software for 19F SSNMR spectra of ASD6 (82% 
AMG 517 in HPMC-AS) after 12 days in the TAM at 80°C/75%RH.  For the deconvolution, the 
blue lines represent the theoretical signals from the individual amorphous and crystalline signals, 
the dark pink line is the addition of those peaks and the lighter trace is the actual data.  The 
residual signal (difference between actual data and additive signal from theoretical peaks) is 
shown in red.  Comparing the fitted areas for the theoretical amorphous and crystalline peaks, % 
crystallinity for the sample is calculated.   
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After de-convolution, the sample shown in Figure 21 is determined to have 59.7% 
crystallinity; that is, 59.7% of the AMG 517 in the sample is in the crystalline form.  The de-
convolution has a calculated error of ~1% for this sample, which is typical of all de-convolutions 
in this study.  The ASD samples contain various levels of crystalline AMG 517 and the de-
convolution results are listed as “% crystalline” in Table 6 and Table 7 for all of the traditional 
solid state stability experiments and TAM crystallization experiments, respectively.  The amount 
of crystallinity determined by 19F SSNMR appears to correlate well with XRPD and mDSC 
analyses.  The % crystallinity results from 19F SSNMR also align well with crystallization 
conditions, with less strenuous conditions of temperature and relative humidity having lower 




Rate constants are calculated for each TAM crystallization sample using the Avrami 
equation, where t is the end of crystallization peak or the end of the experiment time, whichever 
is sooner and X is the percent crystallized, based on 19F SSNMR deconvolution data.   
Since many of the ASD crystallizations with AMG 517 were slow, the TAM experiments 
were run for a maximum of 42 days, so the maximum time used in the Avrami calculations is 42 
days.  Single point calculations were used to estimate Avrami rate constants and n values where 
full rate data was not available from the TAM.  In many cases, the crystallization was too slow to 
observe a clear crystallization event by TAM, although partial crystallization can be measured by 
19F SSNMR.  A lower limit of k is calculated as 6.0 x 10-5/day2 for TAM experiments using t=42 
days, assuming n=2 for rod shaped particles and X=0.1 with 10% crystallization as a “stability 
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failure” criteria.  Rate constants for solid state stability experiments and for TAM crystallization 
experiments are included in Table 6 and Table 7, respectively.   
Table 7.  Estimated rate constant calculations for a single point end point) using 19F SSNMR 
crystallinity & TAM experiment times and n = 2 for calculating Avrami rate constants  











k, (single point) 
ASD2 5075 54 50 75 0 <10 33.2 0.000096 
ASD2 8025 54 80 25 7.8 < 10 42 0.000060 
ASD2 8075 54 80 75 75.9 12.9 0.008551 
ASD3 6550 62 65 50 10.1 42 0.000060 
ASD3 8075 62 80 75 74.8 13.8 0.007238 
ASD4 6550-1 70 65 50 6.3 <10 34 0.000060 
ASD4 6550-2 70 65 50 5.4 <10 42 0.000060 
ASD5 6550-1 75 65 50 5.0 <10 27.8 0.000060 
ASD5 6550-2 75 65 50 4.3 <10 42 0.000060 
ASD6 5075 82 50 75 9.4 <10 33.1 0.000097 
ASD6 6550 82 65 50 11.3 42 0.000068 
ASD6 8025 82 80 25 10.1 42 0.000060 
ASD6 8050 82 80 50 28.7 40.7 0.000204 
ASD6 8075 82 80 75 61.8 11 0.007953 
ASD8 6575 95 65 75 53.5 15.5 0.003187 
ASD7 5050 100 50 50 28.0 37.8 0.000230 
ASD7 5075 100 50 75 96.6 33.2 0.003068 
ASD7 6510 100 65 10 100 40.9 0.004129 
ASD7 6525 100 65 25 100 6.5 0.163497 
ASD7 6550 100 65 50 100 6.75 0.151611 
ASD7 6575 100 65 75 98.3 3.75 0.289745 
ASD7 8025 100 80 25 100 2.3 1.305814 
ASD11 5075d 33 50 75 12.8 42 0.000078 
ASD11 5075nd 33 50 75 11.7 42 0.000071 
ASD11 6575nd 33 65 75 23.7 19.7 0.000697 
ASD11 8075d 33 80 75 55.7 42 0.000462 
ASD11 8075nd 33 80 75 17.6 20.9 0.000443 
ASD12 5075nd 80 50 75 6.7 <10 42 0.000060 
ASD12 8050nd 80 80 50 4.5 <10 42 0.000060 
ASD12 8075d 80 80 75 52.3 9.3 0.008559 
ASD12 8075nd 80 80 75 36.0 9.0 0.005510 




Avrami rate constants are also shown graphically in Figure 22, with larger circle size 
indicating a higher rate constant and faster crystallization of AMG 517 at elevated conditions of 
relative humidity and temperature.   
 




Red – AMG 517 in HPMC-AS  
Blue – AMG 517 in PVP 
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Analysis of Rate Data from TAM Crystallization Experiments 
For experiments which had significant crystallization over the experimental time frame, rate 
data from the TAM was integrated as in Figure 23 and Figure 26, and plotted as in Figure 24 and 
Figure 27, for ASD2 (50% AMG 517 in HPMC-AS) at 80°C/75%RH and ASD6 (82% AMG 
517 in HPMC-AS) at 80°C/75%RH, respectively.  Rearrangement of the Avrami equation allows 
for fitting of the crystallization rate data to obtain the Avrami constants n (geometric factor) and 
k (rate constant), as shown in Figure 25 and Figure 28.  For the crystallization of ASD6 (82% 
AMG 517 in HPMC-AS) at 80°C/75%RH, Figure 22 - 28, the two events are treated separately 
to obtain separate rate constants for each event.  Where two events are apparent, as in Figure 26, 
it is assumed that the heat of crystallization is proportional to the % crystallinity for the entire 
sample, and the two events are treated as if the heat of crystallization is the same.     
       
Figure 23. Raw data showing TAM profile for ASD2 (50% AMG 517 in HPMC-AS) at 
80°C/75%RH integrated at 5-10 hour intervals. 
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Figure 24.  Crystallization Rate profile for ASD2 (50% AMG 517 in HPMC-AS) at 
80°C/75%RH.   
 
 
Figure 25. Fitting of Avrami constants for crystallization rate data for ASD2 (50% AMG 517 in 


















Crystallization Rate Profile  
ASD2 (50% AMG 517 in HPMC-AS) 
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ASD2 (50% AMG 517 in HPMC-AS) 
at 80°C, 75%RH
ln [-ln(1-X)] = n ln t + ln k
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Figure 26. Raw data showing TAM profile for ASD6 (82% AMG 517 in HPMC-AS) at 
80°C/75%RH integrated at 5-10 hour intervals.  
 
 
Figure 27. Crystallization rate profile from integrated TAM data.  Crystallization of ASD6 (82% 
AMG 517 in HPMC-AS) shows two kinetic events, over 300 hours (13 days).   
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TAM Crystallization Rate Data






Figure 28. Avrami fitting of TAM crystallization rate data to obtain Avrami rate constants n and 
k for the two crystallization events observed during the experiment.  Rate constants for the first 
and second kinetic events are fitted separately. 
 
 The Avrami fittings using double ln have some built-in error due to the nature of log-type 
plots, but it is still useful to obtain estimates and to observe crystallization trends relating to drug 
load in the ASDs.  Table 8 shows the rate constants and n constants for the 80°C/75%RH 
crystallization experiments with the TAM.   
Table 8.  Avrami constants after fitting the rate data 
  Avrami rate constant Geometric constant 










ASD2 8075 50 1.07 x 10-5 ‘-- 2.18 ‘-- 
ASD3 8075 62 2.4 x 10-5 7.3 x 10-5 1.92 1.65 
ASD6 8075 82 2.6 x 10-3 8.2 x 10-3 1.06 0.94 
ASD8 8075 95 1.2 x 10-2 1.0 x 10-5 0.33 2.29 
 
y = 1.0613x - 5.936
R² = 0.9952

















Avrami Fitting for 
ASD6 (82% AMG 517 in HPMC-AS) 
at 80°C, 75%RH - 2 events
ln [-ln(1-X)] = n ln t + ln k
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 A plot of log k1 vs ASD drug load, in Figure 29, shows that drug load has an impact on 
crystallization rate constant for ASDs of AMG 517 in HPMC-AS.  The rate constant for the first 
event, k1, is used for the evaluation of drug load, since the first crystallization event is more 
relevant for determining stability of the material.  Considering that the phase separation causing 
the more rapid rate constants above 50% drug load, it may be that miscibility of AMG 517 in 
HPMC-AS is slightly lower than 50% and crystallizations below this level will have similar rate 
constants.  From the graph, it is apparent that the amount of polymer used in the ASD affects the 
stability.  However, ~ 40% polymer (or 60% drug load) appears to be sufficient for obtaining 
maximum stability for the ASD system.  Additional polymer is expected to have a less 
significant effect, as indicated by the leveling off of the curve.   
 
Figure 29.  Avrami rate constant, k1, as a function of drug load of AMG 517 in HPMC-AS 





 Rate predictions based on the Avrami model are only valid within the experimental 
range.  To predict outside this range, extrapolation from the experimental data must be used.  
Arrhenius plots are commonly used for this purpose in chemical degradation studies; here we 
apply the Arrhenius equation to extrapolate from TAM experimental conditions to ambient 
conditions.  An Arrhenius plot is shown in Figure 30 for rate data from the TAM crystallization 
experiments for 75% RH at temperatures of 80°, 65°C, 50°C from TAM.   
 
Figure 30. Arrhenius plot for 75%RH at 80°C, 65°C and 50°C TAM experiments.   
 
Extrapolating to 25°C yields a rate constant value of 1.31x 10-7.  Rearranging the Avrami 
equation for 5% crystallization gives t10% =  [ - ln(1 - 0.1) /k ] ½ , which yields a 10% 
crystallization time of 897 days (~ 2.5 years) for ASDs of AMG 517 in HPMC-AS stored at 
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25°C/75%RH.  This result is consistent with the traditional solid state stability data for ASDs 
stored at 25°C/60%RH, which indicated 6.1% crystallization for ASD6 (82% AMG 517 in 
HPMC-AS) by 19F SSNMR over a storage period of 19 months, and < 10% crystallization by 19F 
SSNMR over a storage period of 19 months for lower drug load ASDs.  Although all the ASDs 
do crystallize at stressed conditions, Arrhenius predictions indicate that for ASDs of AMG 517 
in HPMC-AS, the polymer inhibits crystallization to less than 10% in 2.5 years when stored at 
25°C/75%RH.  This result suggests that at 82% drug load, an amorphous solid dispersion of 





TAM isothermal microcalorimeter is useful in observing crystallization at or above the Tg of 
a material at a given set of temperature and relative humidity conditions.  TAM can detect 
crystallization events when heat flow is > 1µW.  At conditions below the Tg, crystallization is 
much slower, resulting in heat signal so low that it is difficult to identify a single crystallization 
event.  However, SS-NMR confirms partial crystallization of HPMC-AS ASDs even for slow 
crystallizations below Tg. 
Crystallization of ASDs of AMG 517 in HPMC-AS follows the expected trends in terms of 
temperature and humidity (i.e. faster crystallization at higher temperature and humidity 




Adding polymer to AMG 517 significantly slows the crystallization of the drug, with both 
HPMC-AS and PVP.  PVP is not as good as HPMC-AS at stabilizing ASDs.  PVP picks up more 
water than HPMC-AS, causing the ASDs to have lower Tg values at the same crystallization 
conditions.  Also, AMG 517 crystallizes out of PVP in a crystal form which is different from the 
starting material.   
Isothermal microcalorimetry can provide important kinetic data for crystallization of ASDs.  
A dual mechanism observed for crystallization of ASDs indicating phase separation.  Rate 
constants calculated for ASD crystallizations aid selecting drug load for maximizing stability 
while minimizing polymer used in the formulation.  Finally, Arrhenius extrapolation is used to 
predict stability 10% crystallization predicted in 2.5 years at 25°C/75%RH, which is consistent 
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Chapter 5 – Conclusions and Suggestions for Further Study 
Conclusions 
In this project, it is shown that amorphous solid dispersions (ASDs) of AMG 517 in HPMC-
AS manufactured by spray drying from ethyl acetate are initially phase mixed amorphous 
materials.  The residual solvent affects the glass transition temperature (Tg) of ASDs and should 
be dried to < 0.2% ethyl acetate to stabilize the Tg.  Compared to Gordon-Taylor predictions, 
significant depression of the Tg of ASDs of AMG 517 in HPMC-AS is observed.  Negative 
deviation from Gordon-Taylor prediction indicates a thermodynamically unstable ASD system.   
Crystallization studies show the presence of polymer (HPMC-AS or PVP) in ASDs slows the 
crystallization rate of amorphous AMG 517.  Isothermal microcalorimetry is a useful technique 
for observing the crystallization of pure AMG 517, with clear temperature and relative humidity 
trends.  Isothermal microcalorimetry can also be used to observe crystallization of ASDs of 
AMG 517 in HPMC-AS and in PVP.  Crystallization is much slower for ASDs, resulting in low 
heat signals.  At conditions below the Tg of each ASD, the isothermal microcalorimetry signal is 
so low that it gets lost in the noise signal.  Overall, crystallization of ASDs of AMG 517 in 
polymer is observed to be faster at higher temperature and humidity conditions.   
Crystallization rate constants, calculated using isothermal microcalorimetry crystallization 
time and % crystallinity from de-convolution of 19F SSNMR measurements, can be used to map 
the crystallization of AMG 517 ASD system.  19F SSNMR is a powerful tool to quantify the % 
crystalline AMG 517 in each partially crystallized ASD.  Even for crystallizations that are slow 
and have low heat signal, 19F SSNMR shows some crystallized AMG 517, confirming that the 
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kinetically stabilized ASD system does undergo a crystallization process, even at conditions well 
below the Tg.  Compared to PVP, HPMC-AS is a better polymer for kinetically stabilizing ASD 
systems of AMG 517.   
 
Suggestions for Further Study 
There are several opportunities for further investigation, including the evaluation of 
alternative drug and polymer systems for crystallization rate prediction using isothermal 
microcalorimetry.  It appears that AMG 517 is a relatively stable drug and a less stable drug 
would be expected to crystallize faster with potentially higher heat signal, allowing more 
straight-forward microcalorimetry analysis.  Any number of alternative drugs and alternative 
polymers could be evaluated.  In each case, Tg predictions could be correlated with 
crystallization stability conditions.   
There may be value in determining exactly where the ASD interaction is taking place on the 
molecules.  13C SSNMR could be used to identify which carbons on the AMG 517 are 
interacting with the polymer for the phase mixed ASDs.  Molecular modeling could be useful to 
understand the interaction, but is beyond the scope of this work.     
 
